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ABSTRACT

SYNTHESIS, TESTING AND CRYSTALLOGRAPHIC STUDIES OF ALLOSTERIC
MODIFIERS OF HEMOGLOBIN

By Tanvi M. Deshpande, M.S.

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.

Virginia Commonwealth University, 2013.

Major Director: Dr. Martin Safo
Associate Professor, Department of Medicinal Chemistry

The major physiological function of hemoglobin (Hb) is to bind, transport and deliver oxygen to
tissues; made efficient by endogenous effectors, such as protons and 2,3-diphosphoglycerate.
Synthetic allosteric effectors of Hb (AEHs) are also known to modulate Hb oxygen affinity,
showing potential for the treatment of sickle cell disease (SCD) and ischemic-related diseases. In
this project, AEHs which increase Hb affinity for oxygen, including derivatives of the antisickling compounds, 5HMF and benzaldehydes, as well as an AEH that decreases Hb affinity for
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oxygen, RSR-13, were synthesized for their effects on Hb oxygen binding property and their
capability to release NO from substituted nitrate ester moieties. Compounds that were found to
increase Hb affinity for oxygen were further tested for their anti-sickling activities. Structural
studies were carried out to gain insight into the compound’s mode of action. Development of
these agents could be a therapeutic strategy for SCD or ischemic-related diseases.

	
  
	
  

INTRODUCTION

1. Hemoglobin – A target for drug design
Human hemoglobin (Hb) is an allosteric protein that exists between the deoxygenated
(tense or T) and oxygenated (relaxed or R) state.1 The major physiological function of Hb is to
bind oxygen (O2) in the lungs and deliver it to the tissues.2 This function is regulated and/or
made efficient by endogenous heterotropic effectors, such as 2,3-diphosphoglycerate (2,3-DPG),
chloride (Cl-) and hydrogen ions (H+).3 2,3-DPG in the red blood cells (RBCs) preferentially
bind to the deoxygenated Hb and stabilizes the T-state to decrease the Hb affinity for O2.4-6 This
enables adequate O2 release to respiring tissue. Low pH, as a result of metabolism, leads to
uptake of H+ by the protein which also stabilizes the T-state, with a concomitant release of O2 to
the respiring tissues.7-10 Conversely, uptake of O2 by T-state Hb releases the H+ and the bound
2,3-DPG from the T-state, with a concomitant stabilization of the R-state and an increase in the
Hb oxygen affinity.
A number of synthetic allosteric effectors of Hb (AEHs) are also known to bind to the
protein and either increase or decrease its affinity for O2 by stabilizing or destabilizing one of the
Hb states. The ability to allosterically regulate Hb ligand binding has been of significant interest
1	
  
	
  

	
  
	
  

in medicine due to its wide range of applicability. For example, RSR-13 (Efaproxiral),11 and
inositol hexaphosphate (IHPP)12 are AEHs that preferentially stabilize the T-state relative to the
R-state to lower the affinity of Hb for O2 and enhance its delivery to tissues in a manner
physiologically similar to 2,3-diphosphoglycerate (2,3-DPG). Physiologically, Hb releases 25%
of O2 to tissues;13 therefore, these compounds have potential therapeutic applications in treating
ischemia-related cardiovascular diseases, such as angina, myocardial ischemia, stroke, trauma,
where more O2 is needed to heal tissue or organs.14-16
A second class of AEHs, which includes vanillin and 5HMF, on the contrary, bind to Hb
to increase its O2 affinity by preferentially stabilizing the R-state relative to the T-state. These
compounds have been studied for the treatment of sickle cell disease (SCD).17,18 Sickle cell
disease occurs as a result of a single point mutation of βGlu6 in normal hemoglobin (Hb A) to
βVal6 in sickle hemoglobin (Hb S).19,20 This mutation creates a hydrophobic patch that allows
stereospecific interactions between deoxygenated Hb S (deoxy-Hb S) molecules, causing
polymerization inside red blood cells (RBCs).20,21 This leads to deformation of the RBCs into
rigid sickle cells that occlude capillaries and small blood vessels. Compounding this problem is
the fact that sickle Hb has low affinity for O2 due to high concentration content of 2,3-DPG,
resulting in high concentration of deoxy-Hb that polymerize easily.22 Thus, AEHs that are able to
increase O2 affinity of Hb behave as anti-sickling agents by preventing premature deoxygenation
of sickle Hb, as well as reducing the concentration of deoxy-Hb S in RBCs.

2	
  
	
  

	
  
	
  

2. Structure and function of Hb
Hemoglobin is a tetrameric protein with a molecular weight of about 64,500, consisting
of four subunits: two α-subunits (α1 and α2) containing 141 amino acids each, and two β subunits
(β1 and β2) containing 146 amino acids each.23,24 Hemoglobin crystal structure in the liganded
form was first solved by Perutz et al. in 1962 (Figure 1).25 Following that, the structure of the
unliganded (deoxygenated) was determined.26 As shown in Figure 1, each tetramer has one heme
moiety per subunit. The α-subunit consists of seven α helices – A through H with no D, while the
β-subunit comprises of eight α helices – A through H.24,27 The four subunits are arranged into a
distorted tetrahedral geometry showing a two-fold axis of symmetry and forming a large central
water cavity.27 The central water cavity is narrower in the oxy-Hb than in the deoxy-Hb.28	
  The αand β-clefts define the two entry points into the central water cavity, with those of the T-state
larger than the R-state. Each heme moiety has a heme prosthetic group which binds O2. The
heme is coordinated with four nitrogens of the porphyrin ring in the equatorial plane and
histidine (αHis87 at the α-heme and βHis92 at the β-heme) in the axial plane. When O2 binds to
the heme, the iron-histidine residue comes into the plane of the porphyrin ring, whereas when no
ligand is bound to the heme, the iron-histidine residue moves out of the plane of the porphyrin
ring.3
Hemoglobin exists in equilibrium between the R-state having high O2 affinity, and T-state
possessing low O2 affinity state. 3,29 The T-and R-states of Hb provide a structural basis for Hb
cooperativity that facilitates the efficient uptake and release of O2 in vivo.1 Based on the liganded
or oxy-Hb and unliganded or deoxygenated structures of Hb, Max Perutz proposed a
stereochemical mechanism to explain Hb cooperativity.8 He suggested that each subunit of the
Hb tetramer goes through tertiary conformational change upon ligand binding, which is then

3	
  
	
  

	
  
	
  

transmitted to the other subunits through direct communication between them. This leads to
sequential increase in the ligand affinity at other heme sites, and thereby shifting the equilibrium
towards the R-state.8 The converse is true for shifting the equilibrium to the T-state. This
property of hemoglobin is depicted by the sigmoidal curve of O2 binding, which is also known as
oxygen dissociation (ODC) or oxygen equilibrium curve (OEC) (Figure 2).30
Several heterotropic effectors regulate the O2 affinity and cooperative behavior of Hb.
These effectors include 2,3-diphosphoglycerate (2,3-DPG) (1), hydrogen ions (H+), carbon
dioxide (CO2) and chloride ions (Cl−).3,31 This helps in maintaining Hb function of O2 transport
and its delivery, effectively.32 2,3-DPG is an endogeneous allosteric effector of Hb which
preferentially binds to the larger β-cleft of deoxy-Hb and stabilizes the T-state,28 allowing
offload of O2 to the tissues. It does so by tying the two β-subunits together through several
intersubunit hydrogen bond/ salt-bridge interactions to stabilize the T-state.5,28 To transition from
T-state to R-state, the 2,3-DPG – mediated salt bridge/ hydrogen bonds must be broken and the
2,3-DPG expelled out from the water cavity.

O
2-O

3P

O-

O
O

PO 32-

2,3-DPG (1)
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α2	
  

β1	
  

α1	
  

β2	
  

Figure 1. Tetrameric structure of human hemoglobin with α (α1 - blue; α2 - grey) and β (β1 magenta; β2 - yellow) chains and iron containing heme moieties.25
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Figure 2. Sigmoidal curve of hemoglobin on O2 binding.30
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The ligand releasing and binding properties of Hb are also dependent on the pH. The
effect of [H+] on the equilibrium between the T- and R-states is known as Bohr’s effect. In 1904,
Christian Bohr discovered that CO2/H+ have an effect on the O2 releasing or binding property of
Hb. High concentration of CO2 in the tissues reduces the pH causing the O2 affinity of the Hb to
decrease.33 It was shown later by Max Perutz that at acidic pH, protonated β1His146 participates
in salt-bridge interactions with the carboxyl group of β1Asp94 and the amine of α2Lys40, which
stabilizes the low affinity T-state structure to reduce the Hb affinity for O2.8 Vice versa, in the
lungs, where pH is high due to the release of CO2, the O2 affinity of Hb is increased, allowing it
to bind to O2.33 Mechanistically, at higher pH values, the above salt-bridges are broken, which
increase the mobility of β1His146, shifting the allosteric equilibrium to the R-state.8
Fetal hemoglobin (Hb F) is a form of Hb present in neonates until 6 months of age after
which there is a switch from Hb F to adult hemoglobin (Hb A). Hb F contains 2 α-chains and 2
γ-chains (instead of β-chains).34,35 The amino acid sequence in the γ-chain is about 72% similar
to the β-chain. The only difference is that βHis143 is replaced by βSer143.36 This change
eliminates two positive charges from the 2,3-DPG binding site and reduces affinity of Hb F for
2,3-DPG, thereby increasing the O2 affinity of Hb F.37

3. The oxygen equilibrium curve (OEC)
The allosteric equilibrium between the two Hb states (Figure 2 and 3) shows a typical
oxygen equilibrium curve (OEC) for Hb which is a plot of percent saturation of Hb (sO2) against
the partial pressure of O2 (pO2).30 When the allosteric equilibrium shifts towards the R-state
(left-shift of the curve), high affinity Hb is obtained that more readily binds to and holds O2.
While a shift towards the T-state (right-shift of the curve) results in a low affinity Hb that more
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easily offloads O2. The oxygen affinity of Hb is reported as P50, the partial pressure of oxygen in
mmHg at which 50% of Hb is saturated with oxygen.37
Figure 3 shows the shift in the OEC with varying pH, temperature and 2,3-DPG.38 The
middle curve portrays the normal OEC for Hb. A decrease in pH, increase in temperature and/or
increase in the red cell 2,3-DPG value, leads to a right-shift in the curve. This indicates that the
deoxy (T) state of Hb is stabilized and there is a higher degree of O2 release at the same partial
pressure of O2. If there is an increase in the pH, decrease in temperature and/ or red cell 2,3-DPG
concentration, a left-shift in OEC is observed. This indicates that the oxy (R) state is stabilized
and that the O2 affinity of Hb increases.
As noted previously, there are also several allosteric effectors that can modulate the O2
affinity of Hb. These compounds bind to the Hb to shift the allosteric equilibrium from T-state to
R-state or vice versa. This allosteric property has been taken advantage of in medicine. For
instance, agents that left-shift the OEC to produce high-O2-affinity Hb are potentially useful to
treat SCD,39-41 while agents that right-shift the OEC to enhance and/or increase O2 delivery to the
tissues are potentially useful for the treatment of hypoxic and ischemic-related diseases.42
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Figure 3. Oxygen equilibrium (or dissociation) curve of hemoglobin. The normal P50 value is
indicated by dashed lines. The left-shift and right-shift in the curves is associated with various
conditions are indicated by dashed arrows.38
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4.

Abnormal human hemoglobins
Abnormal human Hb can be broadly classified into two general categories of disorders

namely, 1) Quantitative disorder, where there is a defect in the production of one of the subunits,
either total or reduction, as in the case of thalassemia, and 2) where there is production of Hb
variants, that is, structural defect in one of the globin chains, as in the case of SCD.
There are two types of thalassemias: α-thalassemia and β-thalassemia. Decreased production of
α-chains leads to α-thalassemia whereas decreased production of β-chains leads to βthalassemia.43 Figure 4 shows the geographical distribution of sickle cell disease, β-thalassemia
and malaria.44 Since 50 years; scientists have noted the increased prevalence of SCD traits in
malaria prone areas. It was soon discovered that Hb AS heterozygote (Hb A having SCD trait)
has proven to protect from malarial infection and death caused by P. falciparum.45
In 1949, Pauling et al.46 applied the method of electrophoresis to determine that SCD was
caused by point mutation of Hb, where βGlu6 was converted to βVal6. Since then, capillary
electrophoresis has been used to detect additional variants.47 These Hb mutants are mainly
divided into four broad categories that exemplify important features of Hb biology:43
1) Unstable variants, involves loss of heme, followed by precipitation of globin in granular
deposits; 2) High O2 affinity variants, involves Hb with high O2 affinity due to stabilization of Rstate relative to the T-state e.g. Hb Hiroshima (β146His to β146Asp); 3) Low O2 affinity
variants, involves stabilization of T-state Hb (deoxy-Hb) relative to R-state, e.g. Hb Milwaukee;
4) Methemoglobin “M-Type” variants, strongly favors the methemoglobin or the oxidized iron
state. These usually involve change in the ligation of the heme iron e.g. Hb M Boston.
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Figure 4. Geographical distribution of SCD, β-thalassemia and malaria.
A. Distribution of Hb S allele; B. Distribution of malaria.44
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5. Sickle cell disease
Sickle cell disease (SCD) is an inherent genetic disorder characterized by sickled RBCs.48
In 1910, James Herrick, a Chicago physician, reported the presence of sickle-shaped RBCs in a
West Indian student.48,49 Normal RBCs are biconcave, donut shaped and are flexible enough to
easily pass through the blood capillaries (Figure 5).18 On the other hand, sickled cells are sickle
shaped and rigid (Figure 5), and hence cannot pass through blood capillaries freely, obstructing
blood flow (vaso-occlusion).18 This leads to a condition called “painful crisis” which is
characterized by hemolytic anemia, hypoxia, ulcers, stroke, and organ damage.44,48,49 Sickled
blood cells are very fragile, leading to hemolysis causing the release of free Hb into the
circulation. This free plasma Hb is a potent nitric oxide (NO) scavenger and results in the
formation of reactive O2 species such as superoxide and peroxide radicals.44 Furthermore, the
enzyme arginase released from the hemolyzed RBCs can deplete the plasma arginine levels.
Arginine is important for NO production in the body by NO synthase.50 Nitric oxide is a potent
smooth muscle relaxant and plays a critical role in vascular homeostasis by maintaining blood
pressure. It is also a critical regulator of platelet activation and aggregation.51 Deficiency of NO
from blood plasma, due to the scavenging property of cell-free Hb, is one of the symptoms of
SCD and may lead to vaso-constriction followed by hypertension.52
Sickle cell disease is widely prevalent in regions such as Africa, India, Caribbean, Central
Mediterranean, South and Central America.44 More than 100,000 of the population of United
States population suffer from this disease.53

12	
  
	
  

	
  
	
  

Figure 5. A) Normal RBC discocytes, B) Sickle cell RBCs.18

Almost 40 years after Dr. Herrick reported SCD, in 1949, Pauling and colleagues46
identiﬁed electrophoretic anomalies in Hb S and came across the molecular basis for SCD. He
coined the term “molecular disease” for SCD.44 The electrophoretic patterns, as shown in Figure
6,54 determined that Hb S has less negatively charged residues as compared to Hb A, hence, Hb S
migrates faster to the negatively charged cathode than Hb A.46 Patients who are heterozygotes,
showing sickle cell trait and do not have symptoms of the disease, showed a mixture of Hb S and
Hb A bands in the electrophoretic pattern.
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Figure 6. Electrophoretic patterns showing normal, sickle-cell trait and sickle-cell disease Hb.54

In 1957, Ingram sequenced the α- and β-chains of Hb and found a mutation at the 6th
position of the β-chain.19 This mutation was caused by the substitution of glutamic acid (Glu), a
polar amino acid, for valine (Val), a hydrophobic amino acid. This mutation in the amino acid is
due to mutation in the β-globin gene (from A to T).20 In deoxy or T-state, the mutated Val
residue of one Hb S makes contact with a hydrophobic pocket formed by Ala70, Phe85 and
Leu88, which results in the formation of 14-stranded fibers.20,21 These fibers have reduced
solubility and form aggregates which disrupt the cell membrane of RBCs.20 Polymerization is
seen only in deoxy-Hb S since the hydrophobic pocket formed by Phe85 and Leu88 can make
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contact with Val6 only in the deoxy-Hb S. Whereas in the oxy-Hb S, the pocket does not make
hydrophobic contact with Val6,55 and therefore oxy-Hb S does not polymerize due to its
increased solubility of 70 g/dl as compared to 17 g/dl for deoxy-Hb S.56 When Hb S gets reoxygenated at higher pO2 values, the sickling can disappear, and most RBCs eventually return to
a normal shape.57
Other studies on the gelation of deoxy-Hb S and various Hb variants have provided
crucial information on other Hb contact points that are important in stabilizing the Hb S
polymer.58 From the foregoing, it was realized that drugs capable of preventing stereospecific
interactions between deoxy-Hb S molecules and/or increasing the O2 affinity of Hb S should
increase its solubility and prevent cell sickling.

6. Therapeutic strategies for SCD
In the U.S., patients with SCD on an average survive until their 40s and suffer from poor
quality of life and a burden of high medical cost. These statistics are far worse in patients from
third world countries. Although a great deal of work has been done to find a cure for SCD,
hydroxyurea is the only clinically available drug for the treatment of the same.40 Hydroxyurea
enhances the production of Hb F; however it is poorly tolerated and can cause myelosuppression,
requiring frequent monitoring for life-threatening side effects.59 Additionally, many people in the
developing countries do not have access to this drug.59 One reason for the lack of success in
finding a useful anti-sickling agent is due to the large amount of Hb present in the blood that
requires treatment with high doses of a relatively nontoxic drug.18,60 The following categories
describe the current therapeutic strategies directed to treat SCD:

15	
  
	
  

	
  
	
  

a) Natural products:
Several natural products have been reported to have anti-sickling effect.61
The roots of Fagara zanthoxyloides are used in Nigeria and other western African countries. The
active ingredients found in these roots are three divanilloylquinic acids which show anti-sickling
effects.62 Apart from these, vanillic acid (2) and p-hydroxybenzoic acid (3) were also found in
the root extracts, and are suggested to have anti-sickling activities. The unripe fruit or leaf of
Carica papaya, containing phenylalanine (4) and tyrosine (5) is used in SCD.62 Niprisan, an
herbal drug, was introduced in 2006 in Nigeria for the treatment of SCD. It constitutes extracts of
four different plants namely Piper guineese, Pterocapus osun, Eugenia caryophyllum and
Sorghum bicolor.63

Vanillic acid (2)

p-Hydroxybenzoic acid (3)

phenylalanine (4)

Tyrosine (5)

b) Genetic:
In 1948, Watson64 observed that the clinical manifestations of SCD are mild in infants
with high levels of Hb F, as seen in patients from certain regions of Saudi Arabia65,66 and
India.66,67 During the last few decades a lot of effort has been dedicated to the increase in Hb F
levels of patients with SCD. Certain drugs including 5-azacytidine (6),68 gemcitabine (7)69 and
decitabine70 were found to stimulate Hb F synthesis by inhibition of DNA methylation. Other
agents such as erythropoietin,71 hydroxyurea (8),59,60 and butyrate (9)72 were found to increase
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Hb F synthesis. In fact, hydroxyurea is the only FDA approved drug to treat patients with
moderate to severe SCD.18,66

5-Azacytidine (6)

Gemcitabine (7)

Hydroxyurea (8)

Butyrate (9)

Other genetic methods for treatment of SCD include hematopoietic stem cell transplantation,73,74
and blood and bone marrow transplantation.75,76 In 1982, St. Jude’s hospital was the first
organization to find a cure for SCD by bone marrow transplantation method. Despite the
beneficial effects of this method, it has several drawbacks which includes; the risk of bone
marrow rejection, high cost of treatment, graft-versus-host disease and high mortality rates.77

c) Membrane acting drugs:
The polymerization of deoxy-Hb S leads to dehydration of RBCs, which in turn results in
further polymerization of deoxy-Hb S. This vicious cycle is due to the fact that sickled cells have
increased amounts of intracellular Ca2+. This increased Ca2+ concentration causes the activation
of K+ efflux channel leading to dehydration of RBCs. Drugs that prevent loss of ions and water
from the cell will help in preventing polymerization of Hb S. Cetiedel (10),78 a membrane acting
drug, is found to inhibit Na+,K+ and Ca2+,Mg2+ ATPases, which results in the swelling of the red
cell membrane and prevention of dehydration. Clotrimazole (11),79,80 an antifungal drug, and
Bepridel (12),81,82 a Ca2+ channel antagonist, reduced cellular dehydration by blocking Ca2+17	
  
	
  

	
  
	
  

activated K+ channel (Gardos channel), thus maintaining the intracellular concentration of K+.
Oral magnesium,80 which inhibits K+,Cl- co-transport channel, also shows the same effect. Other
membrane active agents include Tellurite83 and L-Arginine (13).84 These compounds are shown
to be toxic and hence not used regularly for SCD.85

Cetiedel (10)

Clotrimazole (11)

Bepridil (12)

L-Arginine (13)

d) Stereospecific Acting Agents:
Since the X-ray crystal structure of Hb was first determined,10,26,86 there have been
several efforts to use it as a target to design stereospecific agents that would specifically interact
with certain regions of Hb to destabilize polymer formation and/or increase the O2 affinity of Hb.
These Hb modifying agents can be divided into three categories namely noncovalent, covalent
and transient covalent acting agents/binders.
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i) Noncovalent Hb binders: These agents bind noncovalently to the Hb S, mostly on the
surface of the protein to destabilize polymers formation.87 A wide variety of agents belong to this
class: Urea (14),88 alkyl urea,89 amino acids like phenylalanine,90 ethanol (15),91 tryptophan
(16),90 and arylalanines,92 aromatic alcohols,93 oligopeptides,93 substituted aromatic carboxylic
acids,94,95 and cromolyn sodium (17).96 One drawback of the noncovalent acting agents is that
large doses are required for the treatment of SCD because of low-affinity to the surface of the
protein.

Urea (14)

Ethanol (15)

Tryptophan (16)

	
  

Cromolyn Sodium (17)

ii) Covalent Hb binders: These agents form covalent interactions with Hb, stabilize the R-state
Hb and/or destabilize the T-state Hb to shift the equilibrium to the R-state resulting in increase in
the O2 affinity of Hb.87 These agents are quite promising since they can be administered at lower
doses and less frequently. However, they lack specificity, in a way that, they could react
covalently with other non-specific enzymes in the body, leading to toxicity. Examples are
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cyanates (18),97 nitrogen mustards (19),98 ethacrynic acid (20),99 aspirin (21),100 acetyl
phosphates (22),101 and cystamines (23).102

	
  	
  

Cyanate (18)

Nitrogen mustard (19)

Ethacrynic acid (20)

	
  

Aspirin (21)

Methyl acetyl phosphate (22)

Cystamine (23)

iii) Transient Covalent binders of Hb: These agents include aldehyde-containing compounds
that covalently interact with the amino terminus of Hb to form Schiff base adducts. These agents
are known as transient covalent because they form transient bonds, which last only for a short
period of time, as the Schiff base exists in equilibrium between the bound and the free state. By
forming Schiff bases, they stabilize the R-state and/or destabilize the T-state of Hb, and increase
the concentration of the more soluble oxy-Hb S to inhibit polymerization of Hb S. Examples of
such compounds include vanillin (24),17,103 pyridoxal (25),103,104 aromatic aldehydes,3 12C79
(27),105 5-hydroxymethyl-2-furfural (5HMF) (29),18 and pyridyl derivatives of benzaldehydes
including INN-312(30) and INN-298 (31).106 Abraham et al.17 reported vanillin (which was
studied in a phase I clinical trial) to bind at the N-terminal αVal1 of the α-cleft, as well as near
αHis103, αCys104, and βGln131, and a site between βHis116 and βHis117, all contributing to its
anti-sickling activity. 5HMF, is a naturally occurring anti-sickling compound found in a variety
20	
  
	
  

	
  
	
  

of foods such as coffee, honey, fruit juices, dried fruits, alcohols etc. It is a promising new antisickling agent that increases the O2 affinity of Hb in blood. It is also found to inhibit sickling of
RBCs.18 It is currently in Phase I/IIa study for SCD treatment.106 Derivatives of vanillin have
also been reported, and some of these compounds show as much as 70-fold more potency than
vanillin. These compounds also increase the O2 affinity of Hb by forming Schiff base adducts
with the N-terminal αVal1.103 Other aldehyde containing compounds include substituted
benzaldehydes, trans-cinnamaldehyde (26) and salicylaldehyde (28).107
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trans-Cinnamaldehyde (26)

	
   	
   	
   	
   	
   	
   	
   	
   	
   	
   	
   	
   	
   	
  

	
  	
  	
  	
  	
  	
  	
  	
  Salicylaldehyde (28)

12C79 (29)

	
  

	
  	
  	
  	
  	
  	
  	
  	
  	
  

	
  

	
  

	
  

INN-312 (30)

INN-298 (31)
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e) Other Agents:
Nitric oxide (NO)108,109 and organic NO releasing agents are used in SCD patients with
NO deficiency. The free Hb present in the blood circulation after RBC lysis is a NO scavenger
and takes up all the NO present in blood circulation. NO is a potent vasodilator, lack of which
causes vaso-constriction and an increase in the blood pressure. Therefore NO therapy is
beneficial in SCD patients to maintain blood homeostasis. In addition to inhalation of NO, some
of the clinically used NO donors include glyceryl trinitrate, sodium nitroprusside and isosorbide
dinitrate, which release NO on in vivo metabolism.126

7. Compounds that bind to Hb and decrease its oxygen affinity
During the search for drugs to treat sickle cell disease, researchers discovered several
compounds including clofibrate94,110 and bezafibrate,111 which were found to lower the Hb O2
affinity instead, by stabilizing the T-state of Hb and improve its O2 releasing capacity. The
potential for use of these compounds to treat ischemic-related diseases were realized, resulting in
the synthesis of more potent right-shifters including RSR-13 (32) and several of its analogs.112,113
Crystallographic study of some of these compounds, including RSR-13 complexed with deoxyHb, shows two molecules of the compound to bind along the central water cavity in a two-fold
symmetry related fashion (Figure 7) to interact with both α- and β-subunits with a series of
hydrogen-bonds and hydrophobic interactions that constrain the T-state Hb and prevent the
allosteric shift to the R-state Hb.28 RSR-13 (Efaproxiral) was studied in several animal models
for improving exercise capacity,114 hypoxia,28 ischemic injuries,14 and strokes. It was also studied
for radiation therapy of hypoxic tumors by increasing the O2 supply to the tumors,115 and was
studied in phase III clinical trial as an adjunct to radiation therapy in the treatment of brain
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metastasis and the treatment of glioblastoma multiforme.113,117 It has also been studied for the
development of blood substitutes.116 Researchers at Virginia Commonwealth University are
currently studying RSR-13 to aid in the therapeutic release of gases, such as NO and CO.3

RSR-13 (32)

Figure 7. Binding of a pair of RSR-13 molecules (red spheres) to deoxy-Hb (PDB ID: 1G9V)
with α (α1- blue; α2- grey) and β (β1- magenta; β2- yellow) chains.28
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RATIONALE, OBJECTIVES AND SPECIFIC AIMS

Rationale
1. Aromatic aldehydes increase the oxygen affinity of Hb resulting in anti-sickling effect
The mutation in Hb S creates hydrophobic interactions between deoxy-Hb molecules,
causing polymerization inside RBCs, typically in capillaries where the partial pressure of O2
(pO2) is low.55,117 This is exacerbated by the fact that Hb S has low O2 affinity due to the high
concentration of 2,3-DPG, causing increased concentration of deoxy-Hb S. Unlike deoxy-Hb S,
oxygenated Hb S (oxy-Hb S) does not polymerize.56 When Hb S gets re-oxygenated at higher
pO2 values, the sickling disappears, and most RBCs eventually return to a normal shape.
Therefore, compounds which are capable of increasing the O2 affinity of Hb S would prevent
premature release of O2 and increase the oxy-Hb S concentration; thus preventing polymerization
and RBC sickling. Several aromatic aldehydes, including 5-HMF (Figure 8a) and vanillin, as
well as pyridyl derivatives of vanillin or benzaldehydes (INN compounds) have been studied for
their anti-polymerization and anti-sickling properties.40,103 These compounds bind to Hb S by
forming a Schiff base adducts between the aldehyde moiety and the N-terminal αVal1 nitrogen at
the α-cleft of Hb (Figure 8b). The binding adds additional inter-subunit interaction across the
subunit interfaces of oxy-Hb that lead to stabilization of the R-state. In contrast, binding at the α24	
  
	
  

	
  
	
  

cleft of deoxy-Hb leads to the destabilization of the T-state. As a result, the allosteric equilibrium
is shifted to the R-state resulting in increased concentration of the more soluble oxygenated
Hb S.18,106

	
  

5HMF (27)
(a)

(b)
Figure 8. Binding of a pair of 5HMF molecules (red spheres) to R2-state Hb (PDB ID: 1QXE)
with α (α1- blue; α2- grey) and β (β1- magenta; β2- yellow) chains.118
Vanillin was studied before 5HMF,17 but because of its low potency and lack of activity
when administered orally, the phase I clinical study was terminated. To improve on the
pharmacological properties (allosteric and anti-sickling potency, and oral bioavailability) of
vanillin, several pyridyl derivatives of vanillin, e.g. INN-312 (30), INN-298 (31), INN-270 (33)
and INN-296 (34) were synthesized and tested.103 Some of these compounds, including INN 270,
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INN-298 and INN-312 showed as much as 70-fold and 2.5-fold more potency than vanillin and
5HMF, respectively, in preventing RBC sickling.106 These compounds also showed longer
duration of action than vanillin and 5HMF.119 Some of the INN compounds such as INN-312
(Figure 9a & 9b) showed dual anti-sickling effect. In addition to increasing the O2 affinity of Hb,
these compounds directly destabilize polymer contacts between deoxy-Hb S molecules to inhibit
RBC sickling as a result of the substituted pyridine-methoxy substituent (ortho to the aldehyde
moiety) being directed towards the surface of the Hb.106 Nonetheless, INN compounds that also
bind and direct their meta-positioned pyridine-methoxy substituent (relative to the aldehyde
moiety) down the central water cavity also showed significant left-shifting and anti-sickling
potencies as a result of additional interactions between the protein and the pyridine-methoxy
substituent.106

	
  

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  

INN-312 (30)

	
  

INN-298 (31)

	
  

INN-270 (33)

INN-296 (34)
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INN-312 (30)
(a)

(b)
Figure 9. Binding of a pair INN-312 molecules (red spheres) to R2-state Hb (PDB ID: 3R51)
with α (α1- blue; α2- grey) and β (β1- magenta; β2- yellow) chains.106
Based on the significant improvement in the pharmacologic properties of the INN
compounds, as well as the dual anti-sickling effect of some of these agents, we decided to
derivatize the INN compounds for further improvement in their pharmacologic properties.
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Structure-based drug design:	
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Figure 10. Basic scaffold of the INN compounds with structural modifications.103
Figure 10 shows the core structure of the INN compounds, and several modifications which
includes the methoxy group positions, the linker between the pyridine ring and the benzaldehyde
ring, and the pyridine nitrogen positions. These modifications have previously been made
culminating in several of these compounds having potent anti-sickling effects, including
INN-312, INN-298, INN-296, etc.103 For this project, we decided to further modify the INN core
structure as summarized in Figure 10 for further improvement in the biological activities of these
compounds. The modifications include:
(1)

Replacing the ether linkage between the pyridine and the benzaldehyde ring with an ester

or amide linkage in addition to varying the position of the methoxy and pyridine-methoxy
substituents on the benzaldehyde ring. Two compounds were synthesized including TD-2 (35)
and TD-3 (36) depending on the availability of starting materials, ease of synthesis, and time
constraints. We hypothesized that these compounds would result in greater left-shifting activities
by binding with higher affinity to the R-state Hb through additional interactions involving the
ester or amide moieties.
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(2)

Introducing a hydroxymethyl group on the pyridine ring in addition to varying the

methoxy and pyridine-methoxy substituent positions was hypothesized to increase the polymer
destabilization property and/or binding affinity of the INN compounds. Based on the observation
that INN compounds with the pyridine-methoxy group ortho (INN-312) or meta (INN-298) to
the aldehyde functional group resulted in significant increase in the left-shifting potencies (with
the former class of compounds exhibiting polymer destabilization effects), we decided to extend
the pyridine-methoxy moieties by incorporating a hydroxymethyl group onto the pyridine ring
for increased biological activities.106 Three compounds, including TD-7 (37), TD-9 (38) and TD8 (39) were synthesized out of all the possible combinations of the substituents depending on the
availability of starting materials, ease of synthesis, and time constraints.
The derivatives are positional isomers (TD-7, TD-8 and TD-9) with difference in the positions of
the methoxy and hydroxymethyl-pyridine-methoxy substituent.

	
  	
  

	
  

	
  

	
  

	
  	
  	
  	
  	
  	
  

TD-2 (35)

TD-7 (37)

TD-3 (36)

TD-9 (38)
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2. Aromatic aldehyde with NO releasing ability will be beneficial for sickle cell disease
One of the indications of SCD is hemolytic anemia.44 In sickle cell patients, the increased
rigidity of sickled RBCs leads to their rupture or lysis, releasing Hb which is a potent scavenger
of NO.120 Along with the property of vascular dilatation, NO is also known to possess antiinflammatory property and it has applicability in neurotransmission.121
Due to this scavenging property of Hb, SCD patients have been shown to suffer from NO
deficiency, which consequently leads to hypertension and inflammation. This has prompted a
great interest in developing means to deliver NO exogenously or enhance endogenous production
for therapeutic purposes.122 For instance, inhaled NO has been shown to have beneficial effects
in SCD patients by reducing the severity and duration of Hb S-induced vaso-occlusive or pain
crisis and provide protection during ischemic related diseases, such as pulmonary arterial
hypertension, cardiovascular diseases and acute lung distress syndrome.123-125 In addition to NO
inhalation, several NO-donating compounds, e.g. aspirin, S-nitrosocysteine, pyrazoles,
polynitroxy-albumin, nitroxic-albumin, detaNONOate, thalidomides, and indoles have been
shown to have vasodilatory effect and/or reduce inflammation and/or hypoxia induce lung
damage in SCD patients or mouse models.126,127
From the foregoing, an anti-sickling agent that not only prevents polymer formation but
also makes NO available to mitigate several SCD pathological conditions, would provide a novel
and rational approach for efficiently preventing/counteracting SCD episodes and help limit
disease progression.
We used our lead anti-sickling compound, 5HMF, as well as some left-shifting
compounds synthesized during this project, including TD-7 (37), TD-9 (38) and TD-8 (39) (see
results below) to introduce nitrate ester moieties, resulting in the synthesis of TD-1 (40), TD-7-1
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(41), TD-9-1 (42) and TD-8-1 (43), respectively. It was hypothesized that in vivo the nitrate ester
would hydrolyze to release NO into the vasculature for its vasodilatory and anti-inflammatory
activities,109 while the released parent aromatic aldehyde compound, would then participate in
Schiff base interactions with the amino group of the N terminal αVal1 to increase the O2 affinity
of Hb S.

	
   	
  

	
  

	
  

TD-1 (40)

TD-7-1 (41)	
  

	
  

	
   	
  

	
  

TD-9-1 (42)

TD-8-1 (43)

3. A right-shifting allosteric effector with NO releasing ability
RSR-13 is a potent AEH that increases the O2 releasing capacity of Hb by decreasing Hb
affinity for O2. The compound binds and stabilizes the deoxy-Hb or T-state Hb relative to the
oxy-Hb and shifts the OEC to the right or T-state to increase the release of O2 to tissues,
potentially useful for treating diseased states that are characterized by O2 deficiency.113,128,129 A
potential problem with the use of right-shifting agent is that excessive tissue oxygenation could
induce secondary vasoconstriction and compromise blood flow.130 It seems that a right-shifting
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agent with the ability to release NO could potentially mitigate this problem by its vasodilation
property. Based on the foregoing, we derivatized RSR-13 with a NO releasing moiety to obtain
the compound DD-1 (44).

DD-1 (44)

Objectives:
There are two main objectives for this project:
(1) Design allosteric effectors of Hb (AEH) that increase the oxygen affinity of Hb (left-shifting
of the OEC) with and without the capability of releasing nitric oxide (NO) for the treatment of
sickle cell disease
(2) Design allosteric effectors of Hb (AEH) that not only decrease the oxygen affinity of Hb
(right-shifting of the OEC) but also capable of releasing nitric oxide (NO) for the treatment of
ischemic-related diseases.
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Specific aims:
There are two specific aims:
Specific Aim 1:
A. Synthesis of allosteric effectors that increase the oxygen affinity of Hb with or without NO
releasing moieties
i. Derivatization of INN compounds by substituting the ether linkage with amide or ester
linkage to obtain TD-2 and TD-3
ii. Derivatization of INN compounds by incorporating hydroxymethyl moiety on the
pyridine ring to obtain TD-7, TD-8 and TD-9
iii. Synthesis of nitrate ester derivatives including TD-1, TD-7-1, TD-8-1 and TD-9-1 that
can act as anti-sickling agents, as well as donate NO to the vasculature.
B. Determine in vitro functional and anti-sickling activities of the synthesized compounds
i.

Concentration- and time-dependent oxygen equilibrium curve study with whole blood
and cell-free Hb

ii.

NO-releasing ability of the nitrate ester derivatives

iii.

RBC morphological (anti-sickling) study

C. Determine the atomic interactions between Hb and selected compounds
D. Stability studies of left-shifting nitrate ester compounds
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Specific Aim 2:
A. Synthesis of nitrate ester derivative of RSR-13 (DD-1) that can act as anti-ischemic agents,
as well as donate NO to the vasculature
B. Determine in-vitro functional and allosteric activity of DD-1
i.

Time-dependent oxygen equilibrium curve study with whole blood

ii.

NO-releasing ability of the nitrate ester derivative

C. Determine the atomic interactions between Hb and DD-1
D. Stability studies of DD-1
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RESULTS

Objective 1: Allosteric effectors of Hb (AEH) that increase the oxygen affinity of Hb (leftshifting of the OEC) with or without the capability of releasing nitric oxide (NO) for the
treatment of sickle cell disease
A. Synthesis of AEHs with or without NO-releasing moieties

i. Synthesis of pyridyl derivatives of benzaldehydes (TD-2, TD-3, TD-7, TD-8, TD-9):
Vanillin, a benzaldehyde, exhibits anti-sickling action by increasing the O2 affinity of Hb, as
well as inhibiting direct polymerization of Hb S.17,103 Derivatization of vanillin by incorporating
substituted methoxy-pyridines on the aromatic aldehyde have resulted in several more potent
anti-sickling pyridyl benzaldehyde compounds (referred to as INN compounds; compounds 30,
31, 33 and 34 or INN-312, INN-298, INN-270 and INN-296 respectively). Some of these
compounds, such as INN-312, INN-298 and INN-270, are 40-90 fold more potent than
vanillin.103 In this project, we decided to modify the INN compounds for further improvement in
their pharmacologic activities. The modifications included (1) replacing the ether linkage that
connects the aromatic aldehyde and pyridine with an ester linkage (bridge), (2) replacing the
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ether linkage with an amide linkage (bridge), (3) incorporating a hydroxymethyl moiety on the
pyridine ring. Five compounds were synthesized which included TD-2 (35), TD-3 (36), TD-7
(37), TD-9 (38) and TD-8 (39).
Compound TD-2 (35) with an ester linkage between the benzaldehyde and pyridine moieties was
synthesized as outlined in Scheme I. Esterification reaction was carried out by linking
isonicotinylchloride hydrochloride (47) to a solution of 2-hydroxy-5-methoxybenzaldehyde (46)
in pyridine at 0 °C to give 35 in 13% yield.
SCHEME I: Synthesis of compound 35a

a

Reagent: (a) pyridine, reflux, 2 h.

Compound TD-3 (36) with an amide linkage between the benzaldehyde and pyridine moieties
was synthesized as outlined in Scheme II. 5-Hydroxy-2-nitrobenzaldehyde (48) was alkylated
using methyl iodide under basic conditions to give 49, followed by reduction of the nitro group
to an amine in the presence of Fe/HCl to give 50. Amidation reaction was carried out by reacting
a solution of 50 in DMF with isonicotinylchloride hydrochloride (47) to give 36 in 10% yield.
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SCHEME II: Synthesis of compound 36a

a

Reagent: (a) CH3I, K2CO3, anhydrous DMF, room temperature, 12 h; (b) Fe, HCl, EtOH, H2O,
reflux, 2 h; (c) isonicotinylchloride HCl, pyridine, CH2Cl2, room temperature, overnight.

Compound TD-7 (37) with a hydroxymethyl group on the pyridine ring was synthesized as
shown in Scheme III. 2-Hydroxy-5-methoxybenzaldehyde (46) and 6-(bromomethyl)-2pyridinemethanol (51) were reacted together under basic condition at room temperature for 12 h
to give 37 in 78% yield.
SCHEME III: Synthesis of compound 37a

a

Reagent: (a) K2CO3, anhydrous DMF, room temperature, 12 h.
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Compound TD-9 (38) with a hydroxymethyl group on the pyridine ring was synthesized as
shown in Scheme IV. 2-Hydroxy-4-methoxybenzaldehyde (52) and 6-(bromomethyl)-2pyridinemethanol (51) were reacted together under basic condition at room temperature for 12 h
to give 38 in 71% yield.
SCHEME IV: Synthesis of compound 38a

a

Reagent: (a) K2CO3, anhydrous DMF, room temperature, 12 h.

Compound TD-8 (39) with a hydroxymethyl group on the pyridine ring was synthesized as
shown in Scheme V. 3-Hydroxy-4-methoxybenzaldehyde (53) and 6-(bromomethyl)-2pyridinemethanol (51) were reacted together under basic condition at room temperature for 12 h
to give 39 in 82% yield.
SCHEME V: Synthesis of compound 39a

a

Reagent: (a) K2CO3, anhydrous DMF, room temperature, 12 h.
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ii. Synthesis of nitrate ester derivatives of 5HMF and pyridyl derivatives of benzaldehydes
(Dual–acting NO–releasing hybrid anti-sickling agents) (TD-1, TD-7-1, TD-8-1 and TD-9-1):

It has been shown that SCD patients have NO deficiency as a result of scavenging of NO by free
Hb S which consequently leads to hypertension and inflammation; common pathological
conditions in SCD.121 We synthesized compounds that combine left-shifting and NO donor
abilities not only to increase the solubility and prevent polymerization of Hb S but also have the
potential to deliver NO to the vasculature. The compounds include the nitrate ester derivative of
5HMF (TD-1 or 40), as well as nitrate ester derivatives of pyridyl derivatives of benzaldehydes
(TD-7-1 or 41, TD-8-1 or 43, TD-9-1 or 42).

Compound TD-1 (40), a nitrate ester of 5HMF, was synthesized as shown in Scheme VI. 5Hydroxymethyl-2-furfural (27) was nitrated directly using lithium nitrate and trifluoroacetic
anhydride under basic conditions at 0 °C to give 40 in 85% yield.
SCHEME VI: Synthesis of compound 40a

a

Reagent: (a) LiNO3, TFAA, Na2CO3, anhydrous CH3CN, 0 °C, 7 h.
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Compound TD-7-1 (41), a nitrate ester of pyridyl derivative of benzaldehyde, was synthesized as
shown

in

Scheme

VII.

Solution

of

2-((6-(hydroxymethyl)pyridin-2-yl)methoxy)-5-

methoxybenzaldehyde (37) was reacted with triphenylphosphine and tetrabromomethane to
yield 54 which was converted to the nitrate ester using silver nitrate at 80 °C to give 41 in 69%
yield.
SCHEME VII: Synthesis of compound 41a

a

Reagent: (a) PPh3, CBr4, anhydrous CH2Cl2, room temperature, 2 h; (b) AgNO3, anhydrous
CH3CN, 80 °C, 2 h.

Compound TD-9-1 (42), a nitrate ester of pyridyl derivative of benzaldehyde, was synthesized as
shown

in

Scheme

VIII.

Solution

of

2-((6-(hydroxymethyl)pyridin-2-yl)methoxy)-4-

methoxybenzaldehyde (38) was reacted with triphenylphosphine and tetrabromomethane to yield
55 which was converted to nitrate ester using silver nitrate at 80 °C to give 42 in 55% yield.
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SCHEME VIII: Synthesis of compound 42a

	
  
a

Reagent: (a) PPh3, CBr4, anhydrous CH2Cl2, room temperature, 2 h; (b) AgNO3, anhydrous
CH3CN, 80 °C, 2 h.

Compound TD-8-1 (43), a nitrate ester of pyridyl derivative of benzaldehyde, was synthesized as
shown

in

Scheme

IX.

Solution

of

3-((6-(hydroxymethyl)pyridine-2-yl)methoxy)-4-

methoxybenzaldehyde (39) was reacted with triphenylphosphine and tetrabromomethane to yield
56 which was nitrated using silver nitrate at 80 °C to give 43 in 81% yield.
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SCHEME IX: Synthesis of compound 43a

	
  
a

Reagent: (a) PPh3, CBr4, anhydrous CH2Cl2, room temperature, 2 h; (b) AgNO3, anhydrous
CH3CN, 80 °C, 2 h.

42	
  
	
  

	
  
	
  

B. In-vitro functional and anti-sickling studies
The synthesized compounds were studied for their effect on Hb affinity for O2 (OEC
study). The nitrate ester compounds were also studied for their ability to release NO (Griess
study). Finally, selected compounds that increase Hb affinity for oxygen were studied for their
ability to prevent RBC sickling (RBC morphological study).
The OEC study was performed for all the synthesized compounds with 5HMF as a
positive control using 3-point tonometry.103 Studies were carried out using normal whole blood
(AA) or sickle whole blood (SS) or cell-free Hb A. The measured pO2 (partial pressure of
oxygen) and sO2 (percent saturation of Hb) values were used to estimate P50 and N values of the
effectors. P50 is the partial pressure of O2 required to achieve 50% Hb saturation. Hill coefficient
(N) is the cooperative binding of O2 or ligand to Hb, and is normally 2.8 for normal human
blood. ΔP50 values were calculated by subtracting the P50 value obtained for Hb post incubation
with the effector from that of the control. A decrease in the P50 value (negative ΔP50) results in
the left-shift of the OEC curve which indicates increased affinity of Hb for O2 as a result of
stabilization of the oxy-Hb or R-state Hb. Such compounds are potential anti-sickling agents
since high-O2-affinity sickle Hb does not polymerize. On the other hand, an increase in the P50
value (positive ΔP50) results in the right-shift of the OEC curve, which indicates stabilization of
deoxy-Hb or T-state Hb. Such compounds allow release of more O2 to tissues, potentially useful
for treating ischemic-related diseases.15
The compounds that were derivatized with nitrate esters were further studied to determine
their ability to release NO from the nitrate ester moieties. NO is detected in the form of nitrite
ions (NO2-) which develops an intense purple color in the presence of Griess reagent. The color
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intensity measured in the form of absorbance is directly proportional to the nitrite concentration
in the sample.10,11
Finally, some of the compounds that left-shift the OEC or increases Hb affinity for O2
were studied for their anti-sickling activity. This involves in vitro RBC morphological (antisickling) studies, which were conducted by our collaborators, Drs. Toshio Asakura and Osheiza
Abdulmalik, from the Children’s Hospital of Philadelphia, (CHOP).

i.

Oxygen equilibrium curve (OEC) studies

a. OEC study of compounds TD-2, TD-3, TD-7, TD-7-1, TD-8, TD-8-1, TD-9 and TD-9-1 with
normal whole blood:
Studies were performed on compounds TD-2, TD-3, TD-7, TD-7-1, TD-8, TD-8-1, TD-9
and TD-9-1 using 100 mM stock solution in DMSO and normal whole blood (AA). As noted
above, TD-2 and TD-3 are the compounds with an ester and amide linkage; TD-7, TD-8 and
TD-9 are the compounds with hydroxymethyl substituent on the pyridine ring, while TD-7-1,
TD-8-1 and TD-9-1 are their respective nitrate ester derivatives. The compound solution was
added to 2 mL of whole blood (Hematocrit value of ~ 34%) to make final drug concentration of
2 mM. Hematocrit or packed cell volume is the % volume of RBCs present in the blood.131 The
solutions were incubated for 1 ½ hours at 37 °C, equilibrated in a tonometer with O2 tensions of
6%, 20% and 40% for 5-7 min each, and pO2 and sO2 values were measured thereafter using
ABL 700 series table top automated blood gas analyzer (Radiometer America, Inc., Westlake,
OH). 5HMF was known to exhibit optimal left-shifting activity between 1 to 2 h with peak effect
at 1.5 h when incubated with whole blood necessitating the use of 1.5 h for the incubation time
for our studies.18,119 The results are shown in Table 1 and Figure 11.
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Table 1. Effects of left-shifting compounds on Hb affinity for O2 with normal whole blood.
ΔP50b

Concentration

P50

(mM)

(mmHg)

5HMF

2

20.2 ± 2.0c†

1.8 ± 0.1c†

-11.1

TD-2

2

30.5d†

2.3d†

-0.8

TD-3

2

44.4d†

1.5d†

+13.1

0.1

30.1d*

2.5d*

-0.5

0.5

25.9

d*

2.1

d*

-4.7

1

23.2d*

1.7d*

-7.4

2

14.3 ± 4.3c†

1.3 ± 0.3c†

-17.0

TD-8

2

25.9 ± 2.5c†

1.9 ± 0.1c†

-5.4

TD-9

2

21.1 ± 1.2c†

1.6 ± 0.3c†

-10.2

TD-1

2

27.4 ± 2.3c†

1.9 ± 0.1c†

-3.9

TD-7-1

2

23.4 ± 1.6c†

1.7 ± 0.1c†

-7.9

TD-8-1

2

30.8d†

2.1d†

-0.5

TD-9-1

2

28.6d†

1.9d†

-2.7

Compound

TD-7

N

a

(mmHg)

All samples were pre-incubated with whole blood (Hct ~ 34%) with the specified compounds at
given concentrations for 1 ½ h. †P50 values of test compounds were calculated using control	
  P50
value of 31.3 ± 1.8 mmHg;	
   †Control N value is 2.6 ± 0.1; *P50 values of test compounds were
calculated using control	
  P50 value of 30.6 mmHg; *Control N value is 2.6;	
  aHill coefficient; bΔP50
is (P50 (control)–P50 (sample)) expressed in mmHg; cmeasurements were conducted in n ≥ 3;
d
measurements were conducted in n < 3. The control experiment without test compound (P50
(control)) contains the same concentration of DMSO used to solubilize the test solution (P50
(sample)).

Although all the compounds were designed to left-shift the OEC and increase the O2
affinity of Hb, quite unexpectedly, TD-3 (amide linker) showed the opposite effect by rightshifting the OEC by ΔP50 of 13 mmHg and decreasing Hb affinity for oxygen (Table 1). The rest
of the compounds left-shifted the OEC by varying amounts. The least potent were TD-2 (ester
linker) and TD-8-1 (the nitrate ester of TD-8) which barely shifted the curve (< 1 mmHg). These
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values are well within the experimental error and may not be significant. The inactivity of TD-2
can be probably attributed to the aldehyde dehydrogenase (ALDH) metabolism or metabolism by
esterases inside the RBCs that cleave or metabolize the ester linkage. The most potent left-shifter
was TD-7 (hydroxymethyl analog of INN compounds) with a ΔP50 shift of -17.0 mmHg; more
potent than 5HMF (ΔP50 of -11.1 mmHg) and comparable in potency with INN-312.119 Studies
also showed a concentration-dependent left-shift of the OEC for TD-7 (Table 1).
Although, the other hydroxymethyl derivatives, including TD-8 and TD-9, left-shifted
the OEC (ΔP50 of -5.4 and -10.2 mmHg, respectively), the shifts were found to be significantly
less than 5HMF, as well as their parent INN compounds (without the hydroxymethyl moiety)
which exhibited ΔP50 of -14 mmHg and -16 mmHg, respectively.119 As discussed below, it is
possible that TD-8 and TD-9 could either be binding to plasma protein or perhaps having
difficulties in RBC permeation.
The nitrate ester derivatives showed 2.5-10 fold less potency when compared with the
parent compounds. This observation is probably due to the fact that the nitrate esters did not
hydrolyze completely to release the parent molecule to effect maximum left-shifting activity
and/or may be due to RBC membrane permeability issues or plasma protein binding. As
expected the compounds have major effect on Hb cooperativity (N values), as the shape of the
OEC changed from sigmoidal to hyperbolic with addition of the compound. Similar effect on
cooperativity has been reported for 5HMF,18 INN-312,103 and RSR-13.116 This is a result of the
effectors stabilizing either the T- or R-state Hb and thus restraining a cross-talk between the Hb
subunits which is important for the T-R transition.
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OEC of left-shifting compounds at 2mM concentration
120
100

sO2 (%)

80

Control
5HMF

60

TD-1
TD-7

40

TD-7-1
20
0
0

20

40

60
80
pO2 (mmHg)

100

120

140

Figure 11. OEC of left-shifting compounds at 2 mM concentration incubated for 1 ½ h.

b. OEC study of compounds TD-1, TD-7, TD-7-1, TD-8 and TD-9 with normal cell-free Hb:
As a result of the weak left-shifting activities of TD-8 and TD-9, and the nitrate ester derivatives,
we further evaluated the activity of some of the compounds, including TD-1, TD-7, TD-7-1, TD8, and TD-9 using cell-free Hb (devoid of any proteins, enzymes, plasma and cell membranes).
This experiment was performed to determine whether the plasma protein or RBC membrane
could have any effect on compound biological activity. Previous studies have shown limited
effect of plasma protein and RBC membrane on 5HMF, INN-312 and INN-298 activities.18,106
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Similar tonometry procedure used on whole blood was used with the cell-free Hb using 2 mM
compound and 12 g/dL of Hb. The results are shown in Table 2.
Table 2. Effects of left-shifting compounds on Hb affinity for O2 with cell-free Hb.
Compound

P50

N

(mmHg)

a

ΔP50b
(mmHg)

Control

12.5

2.6

-

5HMF

8.3

2.0

-4.2

TD-7

7.6

1.8

-4.9

TD-8

7.6

1.9

-4.9

TD-9

6.8

1.7

-5.7

TD-1

8.4

2.0

-4.1

TD-7-1

7.7

2.1

-3.9

All samples were pre-incubated with purified Hb A (Hb ~ 12 g/dL) with the specified compounds
at 2 mM concentrations for 1½ h. aHill coefficient; bΔP50 is (P50 (control)–P50 (sample))
expressed in mmHg; measurements were conducted in n = 1. The control experiment without test
compound (P50 (control)) contains the same concentration of DMSO used to solubilize the test
solution (P50 (sample)).

Unlike the results obtained from the whole blood study (Table 1), the results depicted in
Table 2 show that all compounds exhibit significant left-shift in the OEC with cell-free Hb. TD-8
which barely shifted the OEC with whole blood now showed a shift comparable to TD-7 with
cell-free Hb. TD-9 appeared to be an even more potent left-shifter in cell-free Hb than TD-7,
which was opposite to what was observed with whole blood. Although, the nitrate esters still
show less left-shift compared to the parent compounds, there is still significant improvement in
their left-shifting potency with cell-free Hb. These observations suggest that the reduced leftshifting activities of some of the compounds could be partly due to RBC membrane permeability
and/or plasma protein binding issues.
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c. Time-dependent OEC studies with TD-7:
Studies with INN-312 and INN-298 showed the compounds to exhibit longer left-shifting
effect compared to 5HMF119 prompting us to conduct similar experiments with TD-7 along with
the positive control, 5HMF, all at 0.5 mM concentration for a time period of 1 h – 12 h. The
results are shown in Table 3 and Figure 12.
Table 3. Effect of incubation time on Hb affinity for O2 with whole blood for left-shifting
compounds.
Incubation Time
P50
ΔP50b
Na
(Hours)
(mmHg)
(mmHg)
c
c
1
32.7 ± 0.2
2.5 ± 0.1
2
33.0 ± 0.4c
2.5 ± 0.1 c
c
c
4
33.1 ± 0.6
2.5 ± 0.1
Control
6
34.2 ± 0.3 c
2.5 ± 0.1 c
c
c
10
35.1 ± 0.3
2.5 ± 0.1
12
36.1 ± 0.4 c
2.4 ± 0.1 c
c
c
1
29.8 ± 0.2
2.2 ± 0.1
-2.9
2
29.2 ± 0.3 c
2.2 ± 0.1 c
-3.8
c
c
4
29.2 ± 0.1
2.1 ± 0.1
-3.9
5HMF
6
30.0 ± 0.1 c
2.1 ± 0.1 c
-4.2
c
c
10
31.8 ± 0.1
2.1 ± 0.1
-3.3
12
32.8 ± 0.1 c
2.0 ± 0.1 c
-3.3
c
c
1
28.2 ± 0.9
2.2 ± 0.2
-4.5
2
28.2 ± 0.8 c
2.1 ± 0.1 c
-4.8
4
28.8 ± 0.6 c
2.1 ± 0.1 c
-4.3
TD-7
c
c
6
29.1 ± 0.6
2.0 ± 0.2
-5.1
10
30.6 ± 1.0 c
2.0 ± 0.1 c
-4.5
c
c
12
31.1 ± 0.7
2.0 ± 0.2
-5.0
All samples were pre-incubated with whole blood (Hct ~ 34%) with the specified compounds at
0.5 mM concentrations for the specified time. aHill coefficient; bΔP50 is (P50 (control)–P50
(sample)) expressed in mmHg; cmeasurements were conducted in n ≥ 3. The control experiment
without test compound (P50 (control)) contains the same concentration of DMSO used to
solubilize the test solution (P50 (sample)).
Compound

The P50 values of control were found to increase consistently, with incubation. While the
P50 values for 5HMF seem to return to baseline after 6 h, there was no recovery for TD-7 even
after 12 h suggesting TD-7 will have a longer sustained effect similar to INN-312 (Figure 11). 	
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Time Dependent Study of TD-7
37

P50 (mmHg)

35
33
31

Control
5HMF

29

TD-7

27
25
0

2

4
6
8
Incubation Time (Hours)

10

12

Figure 12. Time dependent studies of TD-7 showing change in P50 value with incubation time.

ii. NO release study for compounds TD-1, TD-7-1, TD-8-1 and TD-9-1
Following the OEC studies, Griess assay was performed on the left-shifting nitrate ester
compounds (TD-1, TD-7-1, TD-8-1, and TD-9-1) to measure the release of NO. Griess assay is a
colorimetric assay, used for detection of NO in the form of nitrite ions (NO!
! ). NO released in
solution is highly unstable, with a half-life of 1 to 30 s. It gets rapidly oxidized to NO!
! which is
detected by the Griess reagent. In this method, NO!
! first reacts with the sulfanilamide present in
the reagent to form a transient diazonium salt. This diazonium salt further reacts with
N-naphthyl-ethylenediamine (NED) to form a stable azo compound which possesses an intense
purple color. The absorbance of the azo compound was measured at 540 nm and was found to be
132,133
directly proportional to the NO!
Sodium nitrite (NaNO2) was
! concentration in the sample.
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used as a standard for the Griess assay. Standard NaNO2 curve was obtained according to an
assay procedure.134 NaNO2 samples in deionized water were prepared of concentrations within
the linear range of the assay (1 – 100 µM). The samples were incubated for 30 min at 37 °C, after
which Griess reagent was added and absorbance was measured at 540 nm. The measured
absorbances were used to obtain a standard curve (Figure 13).134 For the measurement of NO!
!
release for all the test compounds (TD-1, TD-7-1, TD-8-1 and TD-9-1), the absorbances were
extrapolated from the standard NaNO2 curve.

Standard NaNO2 curve( µM)

0.8
0.7

0.68
y = 0.0067x + 0.003
R² = 0.99633

OD at 540 nm

0.6

0.52

0.5
0.43

0.4
0.3

0.26

0.2
0.14

0.1
0.002

0
0

20

40

60
80
NaNO2 (µM)

100

Figure 13. Standard sodium nitrite curve of absorbance vs. concentration.	
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Griess assay was performed according to the literature procedure.135 In this assay, 2 mM
solution of the test compound in DMSO was mixed thoroughly with a freshly prepared solution
of L-cysteine and incubated at 37 °C for 1 h and 16 h under anaerobic conditions. Organic
nitrates require specific thiols such as L-cysteine as co-activators for the release of NO. Thiols
form S-nitroso adducts which consequently release NO. The non-enzymatic reaction of
L-cysteine in vitro is thought to mimic the enzymatic-metabolism of nitrate esters in vivo.136
In vivo, thiols play a regulatory role in targeting NO to the RBCs. It may also be useful in
facilitating NO transportation, prolonging its half-life and alleviate its cytotoxic effects.137-139
Griess reagent was added to each test compound, followed by absorbance measurement at 540
nm. Presence of NO!
! results in the formation of a pink color, the intensity of which is directly
!
proportional to the amount of NO!
! present in the mixture. Table 4 represents NO! release for

compounds TD-1, TD-7-1, TD-8 and TD-9.
Table 4. Absorbance and NO!
! release values for TD-1, TD-7-1, TD-8-1 an TD-9-1
Incubation Time

a
𝐍𝐎!
𝟐 release (μM)

a
𝐍𝐎!
𝟐 release (μM)

(Hours)

after 1 hour

after 16 hours

TD-1

4.02

11.93

TD-7-1

7.61

59.25

TD-8-1

21.94

102.54

TD-9-1

20.45

78.66

a

The 𝑁𝑂!! release (μM) was calculated from the standard NaNO2 curve by extrapolating the
absorbance (nm) of the test compounds against the concentration (μM) of NaNO2.
All four compounds (TD-1, TD-7-1, TD-8-1 and TD-9-1) exhibited nitric oxide release
(4.0 – 21.9 μM range at 1 h and 59 – 102.5 μM range at 16 h) upon incubation in the presence of
L-cysteine. The NO release after 16 h incubation was found to be 3-10 fold higher than 1 h
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incubation. From Table 4, it can be interpreted that for all the compounds, the NO release in the
form of NO!
! is found to increase with time, with TD-1 showing the least release, while TD-8-1
showed the most release.

iii. In vitro RBC morphological (anti-sickling) studies with compounds 5HMF, TD-1, TD-7
and TD-7-1
Our collaborators, Drs. Toshio Asakura and Osheiza Abdulmalik, from the Children’s
Hospital of Philadelphia (CHOP), conducted the in vitro RBC morphological (anti-sickling)
analysis. The anti-sickling effects of 5HMF, TD-7, TD-1, and TD-7-1 were studied by
incubating suspensions of SS cells in the absence or presence of three different concentrations of
the effectors in the presence of air for 1 h at 37 °C followed by incubation under 4% O2 at 37°C
for 5 h. Table 5 represents the concentrations of the effectors along with the % inhibition of
sickling cells.
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Table 5. Effects of various concentrations of compounds on inhibition of SS cell sickling.
Compound

Concentration

Sickled cells (%)

(mM)
5HMF

INN-312

TD-7

TD-8

TD-9

TD-7-1

Inhibition of
sickled cells (%)

1.0

83

17

2.0

65

35

5.0

25

75

0.5

85

15

1.0

66

44

2.0

5

95

0.5

5

95

1.0

5

95

2.0

0

100

0.5

78

14

1.0

72

20

2.0

56

38

0.5

67

26

1.0

59

35

2.0

38

57

0.5

25, most round cells

72

1.0

All spherocytes, more hemolysis

-

2.0

Hemolysis, no sickled cells

100

All samples were pre-incubated for 1 h with various compounds and then incubated under 4%
O2 for 5 h. Hb had a hematocrit of 30%.
Figure 14 represents a graph of sickling inhibition (%) vs. drug concentration (mM).
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In-vitro morphological (anti-sickling) studies
100
90
80
% Sickling

70
60

0.5 mM

50

1 mM

40

2 mM

30

5 mM

20
10
0
5HMF INN-312

TD-7

TD-8

TD-9

TD-7-1

Figure 14. Inhibition of sickling of SS cells by test compounds under 4% O2 at 37 °C for 5 h.
In the absence of test compounds, more that 90% of the Hb underwent sickling in 5 h. In
the presence of the positive control, 5HMF, the percentage of the sickled cells decreased in a
dose-dependent manner with ~35% inhibition at 2 mM concentration. INN-312, the secondgeneration positive control, also decreased the percent of sickled cells in a dose-dependent
manner and inhibited sickling by ~ 95% at 2 mM concentration. Comparing the % inhibition of
5HMF and INN-312 at 2 mM concentration, it can be seen that INN-312 is almost 3-fold more
effective in its anti-sickling properties. Remarkably TD-7 showed a very potent anti-sickling
effect, as much as 95% inhibition at 0.5 mM concentration. A plateau effect was observed as the
concentration of TD-7 was increased. Although, TD-8 and TD-9 showed sickling inhibition in a
dose dependent manner, they did not show as much sickling inhibition as TD-7. TD-8 and TD-9
showed % inhibition of ~ 40% and ~ 60% at 2 mM concentrations. TD-7-1, the nitrate ester
analog of TD-7, showed anti-sickling effect but with significant hemolysis with increased
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concentration from 0.5 mM to 2 mM. The RBCs were observed to swell due to possible
intracellular uptake of water.

C. Structural studies
i. Structural studies of deoxy-Hb in complex with TD-7:
The X-ray structure of the most potent left-shifter, TD-7 in complex with Hb was studied
to elucidate the structural basis of its allosteric and anti-sickling activities. To obtain the cocrystals between Hb and TD-7, Hb was deoxygenated under vacuum, followed by incubation of
the drug, and then crystallized using either low-salt condition (0.2 M sodium acetate trihydrate,
0.1 M sodium cacodylate trihydrate pH 6.5 and 30% w/v PEG 8000) or high-salt condition (3.23.6 M sulfate/phosphate precipitant, pH 6.5), all under anaerobic conditions. For the high-salt
crystallization experiment, we observed two crystal forms; the first crystal which was bigger, and
rectangular in shape and purple in color formed in 3-5 days; the second crystal which appeared in
about 2 months later was much smaller, trigonal bipyrimidal in shape and reddish in color.
Similar observations have been reported with left-shifting compounds when co-crystallized with
deoxy-Hb.106,118 It has been suggested that in a complex mixture of deoxy-Hb and a left-shifting
agent, binding of the AEH to the deoxy-Hb slowly shifts the allosteric equilibrium to the R-state,
increasing the concentration of the R-state Hb, which eventually crystallizes out after deoxy-Hb
crystals have been formed earlier.103 Diffraction dataset are yet to be collected for either crystal
forms since the R crystals are too small for diffraction.
We also co-crystallized deoxy-Hb with TD-7 using low-salt condition. Only one crystal
form (deoxy-Hb) was observed which was dark purple and rectangular in shape and grew to a
size of about 0.2 x 0.3 x 0.4 mm in 3-5 days. Diffraction data was collected, and the crystal
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belonged to P21212 space group. The structure of the deoxy-Hb T-state crystal was determined
by a molecular replacement method with the program Phenix140 using the native human deoxyHb structure (2HHB)26 and the structure refined with the program CNS.141 Detailed
crystallographic data is summarized in Table 6.
The electron density map of complex between deoxy-Hb and TD-7 showed sparse and
broken difference electron density at the α-cleft in a symmetry-related fashion, suggesting very
weak compound binding in two positions (Figure 15). Similar observations have been reported
with other left-shifters bound to T-state structures, which has been suggested to be due to a very
large binding pocket in deoxy-Hb precluding tighter binding, as well as inability of these
compounds to make any inter-subunit interactions with the deoxy-Hb.118 As a result of weak
binding to deoxy-Hb, it is suggested that these molecules, instead of stabilizing the T-state,
rather, destabilize it, shifting the allosteric equilibrium to the R-state. In contrast, left-shifters are
known to bind strongly to the R-state Hb by forming several intersubunit interactions with both
α-subunits, resulting in strong compound densities in this Hb state.118 Due to the weak density
for TD-7, detailed and specific interactions between the molecule and the protein are not
warranted. Nonetheless, from the weak electron density, we could ascertain that the compound
forms a Schiff base interaction with the α1Val1 N, directing the hydroxymethyl-pyridinemethoxy substituent upwards and towards the mouth of the α-cleft (Figures 16 and 17) as
previously observed for INN-312.106 The hydroxymethyl-pyridine-methoxy substituent of TD-7
is directed upwards even further as compared to the pyridine-methoxy substituent of INN-312,
which was consistent with our prediction.106 The bound compound is close and/or appears to
make hydrophobic and/or direct or water-mediated hydrogen-bond interactions with α1Pro77,
α1Asp74, α1Asp75, α1Ser131, α2Thr134, and α2Thr137. Some of these interactions have been
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observed in the INN-312 structure.106 The apparent hydrophobic contact with α1Pro77 and
water-mediated interaction with α1Asp75 or α1Asp74 (residues that are on the surface of the
protein) is most interesting as the adjacent residue α1Asn78 has been implicated in Hb S polymer
contact (Figure 18).58 Thus contact between TD-7 and these residues could lead to destabilization
of the Hb S polymer as previously suggested.103
Although, we are yet to collect diffraction data for the R-state crystal, it is anticipated that
like INN-312,106 TD-7 would also bind to the α-cleft of the oxygenated Hb very strongly to tie
the two α-subunits of the liganded Hb together that would stabilize and shift the allosteric
equilibrium to the R-state. Also, the binding would direct the hydroxymethyl-pyridine-methoxy
substituent toward the surface of the protein as observed in the above deoxy-Hb structure, as well
as in the previously published R-state structure in complex with INN-312.106
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Table 6. Crystallographic data and refinement statistics for compound TD-7: Hb complex
Parameters
TD-7
Data-collection Statistics:
Space group

P21212

Unit-cell parameters (Å)

63.2 82.8 110.9 90.0 90.0 90.0

Molecules in asymmetric unit

1

Resolution (Å)

29.78 – 2.00 (2.07 – 2.00)

No. of measurements

148961

Unique reflections (I/σ(I))

33027

Avg redundancy

4.51 (4.46)

Completeness (%)

82.4 (89.9)

Rmerge (%)

0.096 (0.355)
Structure Refinement:

Resolution limits (Å)

30.00 – 2.00

No. of reflections

32997 (82.4%)

R factor (%)

24.02

Rfree (%)

29.59
R.m.s.d from standard geometry:

Bond lengths (Å)

0.009

Bond angles (°)

1.46
Dihedral angles:

Most favored (%)

540 (95.74)

Allowed regions (%)

21 (3.72)
Average B factors (Å)

All atoms

30.8

Protein

30.7

Heme

29.4

Water

37.2

59	
  
	
  

	
  
	
  

Figure 15. Binding of a pair TD-7 molecules (green sticks) at the α-cleft of Hb with the α (α1blue; α2- grey) and β (β1- magenta; β2- yellow) chains.
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Figure 16. A pair of TD-7 molecules (green stick) bound at the α-cleft of T-state Hb making
Schiff base interactions with αVal1 N (blue and grey sticks), as well as showing disposition of
the hydroxymethyl moiety towards the surface of the molecule to make contact with the surface
F helix residues. For brevity, not all residues making contact with the molecule are shown.
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αVal1

TD-7
F-helix

F-helix
TD-7

αVal1

Figure 17. Binding of a pair TD-7 molecules (green sticks) to the F-helix of Hb with α (α1- blue;
α2- grey) chains.
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α1Met76

α1Asp75

α1Pro77

α1Asp74
α1Val73

α1Val1

α1Ser131

α2Ser138
α2Thr134
α2Thr137

Figure 18. Two-dimensional schematic of contacts between TD-7 and the surrounding Hb
residues.
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ii. Structural studies of deoxy-Hb in complex with TD-1
We have also determined the crystal structure of TD-1 (nitrate ester derivative of 5HMF)
to explain its allosteric activity. To obtain co-crystals, Hb was deoxygenated under vacuum,
followed by incubation of the drug, and then crystallized using high-salt condition (3.2-3.6 M
sulfate/ phosphate, pH 6.5) under anaerobic conditions. Only T-state crystals were obtained
belonging to P21 space group, and isomorphous to known native T-state crystal (2HHB).26 The
crystals were dark purple and rectangular in shape and grew to about 0.2 x 0.3 x 0.4 mm in
3-5 days. Detailed crystallographic data is summarized in Table 7. The isomorphous native
deoxy-Hb structure (2HHB) was used for structure refinement.26 The initial electron density map
showed two molecules of TD-1 forming Schiff base interactions with αVal1 N of both αsubunits at the α-cleft in a symmetry-related fashion (Figures 19 and 20). Unlike TD-7, the
ligand density of TD-1 was very strong and well defined, allowing unambiguous fitting of the
ligand into the density for subsequent refinement. This is in contrast with 5HMF (the parent
compound), which like all left-shifters binds weakly to T-state Hb.118 Obviously, the apparent
strong binding of TD-1 to the T-state Hb is consistent with its significantly less left-shifting
effect as binding to the T-state leads to apparent stabilization of this allosteric form.
In addition to the Schiff base interaction with the α1-subunit, the TD-1 furan oxygen
forms inter-subunit water-mediated hydrogen bonds with the symmetry-related α2-subunit with
the amide oxygen of α2Ser138 and the carboxyl atom of α2Arg141 (Figure 21). The ester
oxygen makes hydrogen-bond interaction with the amine of α2Arg141, while the two free nitro
oxygens make either interaction with a water molecule or with the amide oxygen of α2Thr137.
These interactions serve to tie the α1 and α2 subunits together and stabilize the T-state Hb. The
second TD-1 molecule binds in a symmetry-related fashion to the first TD-1 molecule. Although,
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refinement of the structure suggested the bound compound to be mostly the non-hydrolyzed
nitrate ester analog, there is some presence of the hydrolyzed 5HMF. The fact that most of the
bound compound is the nitrate ester analog which apparently is stabilizing the T-state structure,
is consistent with the functional/biological studies that show limited left-shifting and/or antisickling effect of this compound. Thus, for this compound to be effective as an anti-sickling
agent, it must release the NO prior to binding to Hb and not bind as the nitrate ester.
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Table 7. Crystallographic data and refinement statistics for compound TD-1: Hb complex
Parameters

TD-1
Data-collection Statistics:

Space group

P21

Unit-cell parameters (Å)

62.3 82.0 53.5 90.0 99.5 90.0

Molecules in asymmetric unit

1

Resolution (Å)

29.92 – 1.80 (1.86 – 1.80)

No. of measurements

187917

Unique reflections (I/σ(I))

46300

Avg redundancy

4.06 (3.81)

Completeness (%)

94.1 (89.4)

Rmerge (%)

0.039 (0.082)
Structure Refinement:

Resolution limits (Å)

30.0 – 1.8

No. of reflections

46300 (94.1%)

R factor (%)

16.71

Rfree (%)

19.22
R.m.s.d from standard geometry:

Bond lengths (Å)

0.010

Bond angles (°)

1.566
Dihedral angles:

Most favored (%)

548 (96.82%)

Allowed regions (%)

17 (3.72%)
Average B factors (Å)

All atoms

15.1

Protein

12.8

Heme

10.6

Water

27.8

TD-1

30.9
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Figure 19. Binding of a pair TD-1 molecules (green sticks) at the α-cleft of Hb with α (α1- blue;
α2- grey) and β (β1- magenta; β2- yellow) chains.
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αVal1

TD-1

F-helix

F-helix
TD-1

αVal1

Figure 20. Binding of a pair TD-1 molecules (green sticks) to the F-helix of Hb with α (α1- blue;
α2- grey) chains.

α1Val1
O α2Thr137
OT2 NZ

O α2Ser138

α2Arg141

Figure 21. Two-dimensional schematic of contacts between TD-1 and the surrounding Hb
residues. Narrow dashed lines indicate hydrogen bond and electrostatic interactions.
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D. Stability studies of left-shifting nitrate ester compounds
Nitrate esters are known to be unstable and easily prone to hydrolysis.144 The stability of the
nitrate ester derivatives were checked by performing UPLC-MS on previously prepared stock
solutions of the nitrate ester compounds (TD-1, TD-7-1, TD-8-1 and TD-9-1). 100 µM stock
solutions were prepared in DMSO and stored for 3 months at −20°C during which time it was
exposed to at least 6 freeze-thaw cycles. It was observed that the compounds were stable,
suggesting no degradation.

Objective 2: Allosteric effectors of Hb (AEH) that decrease the oxygen affinity of Hb (rightshifting of the OEC) with the capability of releasing nitric oxide (NO)
A. Synthesis of nitrate ester derivative of RSR-13
RSR-13 is an allosteric effector of Hb that acts by decreasing Hb affinity for O2, and as a
result allows release of more O2 to tissues.15 We decided to incorporate a nitrate ester moiety
onto RSR-13. We propose that, in vivo, the NO will cleave off, resulting in the parent compound
and free NO, the former acting as right-shifter while the latter is released into the vasculature.
Compound DD-1 (44), a nitrate ester derivative of RSR-13, was synthesized as shown in Scheme
X. 2-Bromoethanol (57) was nitrated using a nitrating mixture of 95% sulfuric acid and 75%
nitric acid at 0 °C to yield 58 which was coupled with RSR-13 (30) under basic conditions to
yield 44 in 83% yield.
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SCHEME X: Synthesis of compound 44a

	
  

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  

	
  

a

Reagent: (a) H2SO4, HNO3, CH2Cl2, room temperature, 3 h; (b) RSR-13 (30), K2CO3,
anhydrous DMF, room temperature, 24 h.

B. In-vitro functional studies
i.

Oxygen equilibrium studies

a. Time-dependent OEC studies with DD-1 and RSR-13 with whole blood:
The effect of the nitrate ester derivative of RSR-13 (DD-1) was also studied using whole
blood with RSR-13 as a positive control. The solution of DD-1 and RSR-13 was added to 2 mL
of whole blood (Hemocrit of ~ 29%) to make a final drug concentration of 2 mM.
Time-dependent studies were carried out at various time points (ranging from 1 h to 12 h) at
37 °C, equilibrated in a tonometer with oxygen tensions of 6%, 20% and 60% for 5-7 min each,
and pO2 and sO2 values were measured thereafter.
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Table 8. Effect of incubation time on Hb affinity for O2 with normal whole blood for rightshifting compounds.
Compound

Control

RSR-13

DD-1

ΔP50b

Incubation

P50

Time (Hours)

(mmHg)

1

32.5

2.6

-

2

32.9

2.7

-

4

33.6

2.6

-

8

34.9

2.5

-

12

37.0

2.5

-

1

47.8

1.8

15.3

2

47.9

1.9

15.0

4

49.7

1.8

16.1

8

51.8

1.8

16.9

12

52.6

1.9

15.6

1

35.7

2.3

3.2

2

39.2

2.1

6.3

4

49.9

1.9

16.3

8

60.3

1.7

25.4

12

64.8

1.7

27.8

N

a

(mmHg)

All samples were pre-incubated with whole blood (Hct ~ 29%) with the specified compounds
at 2 mM concentrations for the specified time. aHill coefficient; bΔP50 is (P50 (control)–P50
(sample)) expressed in mmHg. The control experiment without test compound (P50 (control))
contains the same concentration of DMSO used to solubilize the test solution (P50 (sample)).

The results showed a gradual increase in the P50 values with time, with a maximum P50
after 12 h incubation. Initially, P50 value of DD-1 was lower than that of the parent compound
but as the incubation time crossed 4 h, the P50 value of DD-1 was seen to increase over the parent
compound. Based on these results, it can be construed that the nitrate ester analog, DD-1, has a
better O2 releasing capacity as compared to RSR-13 after 4 h of incubation.
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Time Dependent Study of RSR-13 and DD-1
70
65
60
p50 (mmHg)

55
50
45

p50 (RSR-13)

40

p50 (DD-1)

35

p50 (control)

30
25
20
0

2

4
6
8
10
Incubation Time (hours)

12

14

Figure 22. Time dependent studies of DD-1 and RSR-13 showing changes in P50 with incubation
time.
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ii. Nitric oxide release study for DD-1
Griess assay was used to measure the NO releasing ability of DD-1 following the
literature procedure (also used for the left-shifting compounds).133 NO!
! release from the
compound was calculated by extrapolating the absorbance of the test compound against the
concentration of NaNO2 in the standard NaNO2 curve (Figure 13). Table 9 represents NO!
!
release for compound DD-1.
Table 9. Absorbance and NO!
! release values for Compound DD-1.
Incubation Time

𝐍𝐎!
𝟐 release (μM) after 1

𝐍𝐎!
𝟐 release (μM) after 16

(Hours)

hour

hours

DD-1

9.61

5.35

a

The 𝑁𝑂!! release (μM) was calculated from the standard NaNO2 curve by extrapolating the
absorbance (nm) of the test compounds against the concentration (μM) of NaNO2.
Unlike the nitrate esters of the left-shifting agents, the NO!
! release from DD-1 after 1 h
incubation was found to be much higher than that after 16 h incubation. DD-1 released NO!
! but
significantly less than the left-shifting compounds shown above in Table 4. This suggests that the
potent OEC effect is most likely due to the binding of the non-hydrolyzed DD-1 to deoxy-Hb.
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C. Structural studies
i. Crystallographic results of DD-1:
The crystal structure of DD-1 was determined in complex with deoxy-Hb, to elucidate
the structural basis of its allosteric activity. To obtain co-crystals, Hb was deoxygenated under
vacuum, followed by incubation of the drug, and then crystallized using low-salt condition
(0.2 M sodium acetate trihydrate, 0.1 M sodium cacodylate trihydrate pH 6.5 and 30% w/v PEG
8000) under anaerobic conditions. The crystals were dark purple, rectangular in shape and
formed quickly growing to a size of about 0.2 x 0.3 x 0.4 mm in 3-5 days. The crystal has space
group P21212. Detailed crystallographic data is summarized in Table 10. The structure was
determined by molecular replacement method with the program Phenix,140 using the deoxy-Hb
structure in complex with RSR-13 (PDB ID: 1G9V)28 as the search model. The structure was
refined with the program CNS.141
The electron density map showed two well defined DD-1 bound in a symmetry-related
manner at the middle of the central water cavity (Figures 23 and 24); similar to what was
previously observed for RSR-13.28 Interestingly, the structure showed a mixture of the nitrate
ester analog (DD-1) and the hydrolyzed analog (RSR-13) and were refined together. In addition
to the bound DD-1, we also observed a 2,3-DPG molecule, bound at the β-cleft (Figure 24).
Apparently, 2,3-DPG was present in the Hb that was used for the crystallization experiment.
Sephadex G25 and extensive dialysis were used to purify the Hb which did not lead to complete
removal of 2,3-DPG, suggesting that a more extensive purification process is required to
completely exclude out the 2,3-DPG. Interestingly, even though the same Hb was used to cocrystallize with the left-shifting agent, TD-7, we did not observe any significant bound 2,3-DPG
at the β-cleft. This could be explained by the fact that binding of the potent right-shifter, DD-1,
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increased the T-state character of the deoxy-Hb which led to stronger affinity for 2,3-DPG. On
the other hand, the binding of the potent left-shifter TD-7 seemed to decrease the T-state
character of deoxy-Hb which reduced 2,3-DPG binding.
Each DD-1 molecule forms interactions with 3 subunits, 2 α-subunits and 1 β-subunit in a
symmetry-related fashion (Figure 25). Relatively weak electron density was observed for the
nitrooxyethylene moiety of the compound, suggesting the bound compound to be a mixture of
hydrolyzed RSR-13 and non-hydrolyzed DD-1. The nitrate group is involved in direct hydrogenbond interaction with the hydroxyl of α1Thr134, water-mediated hydrogen bond interactions
with amide nitrogen of α1Val1 and hydroxyl of α1Ser131 as shown in Figure 26. The oxygen
adjacent to the carbonyl group forms water-mediated hydrogen bond interaction with the amide
nitrogen of α1Thr134, as well as inter-subunit water-mediated hydrogen bond interaction with
the amine of α2Arg141, the latter observed in RSR-13 binding.28 Also, similar to RSR-13
binding,28 the isopropyl group and phenyl group makes several intra- and inter-subunit
hydrophobic interactions with β1Tyr35, β1Trp37, α2Thr137, α2Tyr140 and α2Pro95, while the
carbonyl oxygen makes direct hydrogen bond interactions with the amine of α1Lys99. The
amide nitrogen is also involved in several water-mediated interactions with α1His122,
α1Asp126, while the dimethylbenzene ring makes hydrophobic interactions with α1Phe36,
α1Val96, α1His103 and α1Leu100. As previously noted,28 these interactions serve to tie three of
the subunits together stabilizing the deoxy-Hb to shift the allosteric equilibrium to the T-state
and decreasing the O2 affinity of Hb. It is interesting to note that irrespective of whether the
compound is the hydrolyzed RSR-13 or the non-hydrolyzed DD-1, it binds the T-state Hb in
similar fashion.28
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Table 10. Crystallographic data and refinement statistics for compound DD-1: deoxy-Hb
complex
Parameters

DD-1
Data-collection Statistics:

Space group

P21212

Unit-cell parameters (Å)

95.9 98.4 65.4 90.0 90.0 90.0

Molecules in asymmetric unit

1

Resolution (Å)

29.54 – 1.85 (1.92 – 1.85)

No. of measurements

291228

Unique reflections (I/σ(I))

52662

Avg redundancy

5.53 (4.00)

Completeness (%)

98.2 (94.3)

Rmerge (%)

0.084 (0.313)
Structure Refinement:

Resolution limits (Å)

30 – 1.85

No. of reflections

52628 (98.2%)

R factor (%)

22.38

Rfree (%)

26.38
R.m.s.d from standard geometry:

Bond lengths (Å)

0.12

Bond angles (°)

1.67
Dihedral angles:

Most favored (%)

539 (95.97)

Allowed regions (%)

25 (4.43)
Average B factors (Å)

All atoms

24.1

Protein

22.1

Heme

20.5

Water

35.4

DD-1

48.7

2,3- DPG

43.7
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Figure 23. Binding of a pair DD-1 molecules (green sticks) to three subunits of deoxy-Hb with α
(α1- blue; α2- grey) and β (β1- magenta; β2- yellow) chains.
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Figure 24. Binding of a pair of DD-1 molecules (green sticks) to 2α (blue and grey ribbons) and
1β subunit (magenta ribbon) at the middle of the central water cavity, and binding of 2,3-DPG
molecules in two alternate conformations (dark green sticks) to the β-cleft (magenta and yellow
ribbons).
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Figure 25.	
  	
  Contacts between DD-1 molecules (green sticks) and the protein (α chains- blue and
grey lines, β chains- magenta and yellow lines).
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Figure 26. Two-dimensional schematic of contacts between DD-1 and surrounding Hb residues.
Narrow dashed lines indicate hydrogen bond and electrostatic interactions; broad dashed lines
hydrophobic contacts.
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D. Stability studies of DD-1
Nitrate esters are known to be unstable and easily prone to hydrolysis.144 The stability of nitrate
ester was checked by performing UPLC-MS on previously prepared stock solution of DD-1. 100
µM stock solution was prepared in DMSO and stored for 3 months at −20°C during which time it
was exposed to at least 6 freeze-thaw cycles. It was observed that DD-1 was stable, suggesting
no degradation.
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DISCUSSION

1. Allosteric effectors of Hb that increase the oxygen affinity of Hb (left-shifting of the
OEC) with or without the capability of releasing NO
Sickle cell disease is a hemoglobinopathy which is caused by an abnormal defect in the
β-globin chain of Hb.20 Since hydroxyurea is the only clinically useful drug approved for the
treatment of SCD,59,60,118 there is a need for novel anti-sickling left-shifting agents which would
be beneficial in treating SCD. Hb S in sickle cells has low O2 affinity with a P50 value of
32 ± 2 mmHg as compared to 26 ± 2 mmHg for normal RBCs.106 This leads to premature release
of O2 prior to reaching tissues and organs, depriving them of O2, resulting in hypoxia. In
addition, increased de-oxygenation of Hb S leads to polymerization and sickling of RBC,
eventually resulting in hemolysis. Therefore, one of the potential treatment options for SCD
would be to design compounds that could increase the O2 affinity of Hb S to prevent the
premature release of O2 as well as decrease the concentration of deoxy-Hb S.
This has encouraged the study of several aromatic aldehydes that are known to increase
the O2 affinity of Hb, by forming Schiff base adducts between the aldehyde moiety and the
amino group of N-terminal Val1 at the α-cleft of both deoxy-Hb and oxy-Hb.103,107,118 This
interaction leads to destabilization of the deoxy-Hb and/or stabilization of the oxy-Hb, shifting
the allosteric equilibrium to the high O2 affinity R-state Hb. The compound-modified Hb S acts
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similarly as normal Hb, preventing premature release of oxygen, and releasing just enough O2 in
the capillaries but not extensively to reach the critical deoxy-Hb concentration to polymerize.39
Two such studied compounds include 5HMF and vanillin. 5HMF, is currently being studied
clinically for the treatment of SCD,18 while vanillin has previously been studied for its antisickling activity, both in vitro and in vivo, as well as clinically.103 INN compounds, belonging to
the series of pyridyl derivatives of vanillin or substituted benzaldehydes (INN-270, INN-296,
INN-298, and INN-312), were synthesized by our group to improve on the pharmacologic
properties of vanillin.103 Some of these compounds exhibited more than 70-fold anti-sickling
activity as compared to vanillin, and 2.5-fold more than 5HMF.103,119 More interestingly, some
of the INN compounds (those with the pyridine-methoxy substituent ortho to the aldehyde
moiety), e.g., INN-312 exhibit dual anti-sickling activity by increasing Hb affinity for O2, as well
as destabilizing Hb S polymer contact as a result of the displacement of the pyridine-methoxy
moiety towards the surface of the protein.106 Even those compounds with the pyridine-methoxy
substituent (meta to the aldehyde moiety, e.g., INN-298) directed down the central water cavity,
also showed significant anti-sickling activity as a result of several additional interactions
between the pyridine-methoxy substituent and protein.106
Based on the positive outcome of the modification of vanillin to obtain the INN
compounds, our group decided to further improve on the allosteric, anti-sickling and
pharmacokinetic properties of these compounds, as well as combine their anti-sickling activities
with NO releasing capability. First, analogs of the previously studied INN compounds103 were
synthesized by replacing the ether linkage between the pyridine and benzaldehyde rings to an
ester linkage to yield TD-2 and amide linkage to yield TD-3. The synthesis was carried out as per
Scheme I and II. The final step in the synthesis of compound 50 (Scheme II) involved reduction
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of the nitro group to the corresponding amine. Various reaction conditions were carried out such
as Fe/HCl, Fe/AcOH, Fe/HCl with NH4Cl and hydrogenation with Pd/C, all of which resulted in
poor yields, which could be attributed to the formation of inter- and/or intra-molecular Schiff
base formation between the aldehyde and the amino group. The reaction conditions of Fe/HCl
gave the best yield (17%) amongst the rest, and hence was the method used for the synthesis of
compound 50. The syntheses of TD-2 and TD-3 were carried out by simple base catalyzed
reactions in the presence of pyridine to give the desired products in fairly good yields. Second,
hydroxymethyl group was incorporated onto the pyridine ring which would either extend the
hydroxymethyl-pyridine-methoxy substituent further down the central water cavity to increase its
binding affinity (for compounds that have the substituent meta to the aldehyde) or extend the
hydroxymethyl-pyridine-methoxy substituent to the surface of the protein (for compounds that
have the substituent ortho to the aldehyde) and thus increase its direct polymer destabilization
property. Accordingly, the INN analogs including TD-7, TD-9 and TD-8 with hydroxymethyl
substituents on the pyridine rings were synthesized as shown in schemes III – V. The syntheses
of TD-7, TD-9 and TD-8 were carried out by straight forward base catalyzed reactions in the
presence of K2CO3 to give the desired products in fairly good yields.
A major pathophysiology of SCD is the vascular NO deficiency which is caused due to
NO scavenging by free hemolyzed Hb. To prevent vaso-constriction and inflammation
characterized by this deficiency, exogenous NO, either in the form of gas inhalation or via
organic compound has been studied for making NO bioavailable to SCD patients.44,108
The hydroxymethyl substituents on the compounds 5HMF, TD-7, TD-8 and TD-9 were
esterified with NO releasing moiety. It was proposed that these nitrate esters would hydrolyze in
vivo to release NO and make available to the vasculature, while the parent aromatic aldehydes
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would bind to Hb and display their anti-sickling activities. The syntheses were carried out as per
schemes VI - IX resulting in the compounds TD-1, TD-7-1, TD-9-1 and TD-8-1. 5HMF was
converted directly to its nitrate ester analog (TD-1, Scheme VI) using LiNO3 and TFAA. Similar
reaction condition was tried for the synthesis of TD-7-1, however the reaction was unsuccessful.
Hence, a two-step approach was undertaken which involved conversion of the hydroxymethyl
group to its corresponding bromomethyl, followed by reaction with AgNO3 to yield TD-7
(Scheme VII). Similarly, TD-9 (Scheme VIII) and TD-8 (Scheme IX) were synthesized.
Following the synthesis, the compounds were tested for their effect on Hb affinity for
oxygen, their ability to release NO, their effect on RBC sickling and finally X-ray structure
determination to gain insight into their allosteric properties.

A. Modification of the ether bridge of pyridyl derivatives of benzaldehydes with an ester
or amide resulted in compounds that decrease Hb oxygen affinity
The compounds with an ester or amide bridge were hypothesized to bind to Hb and shift
the O2 equilibrium to the R-state. Unexpectedly, TD-2 did not significantly affect Hb allosteric
property, while TD-3 significantly right-shifted the OEC to decrease Hb affinity for O2 (Table 1).
This suggests that these compounds, especially TD-3 may not be suitable for the treatment of
SCD as they could potentially promote polymerization by increasing the concentration of the less
soluble deoxy-Hb S molecules. Structural studies on atomic level are yet to be performed to
understand the reason why these molecules acted opposite to what was expected. The inactivity
of TD-2 could be probably attributed to aldehyde dehydrogenase (ALDH) metabolism or
metabolism by esterases inside the RBCs that cleave or metabolize the ester linkage and
inactivate it. It is possible the amide analog (TD-3) binds strongly to deoxy-Hb and stabilize the
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T-state Hb, leading to a shift in the allosteric equilibrium to the low O2 affinity Hb. It has been
noted that, aromatic aldehydes with carboxylate groups on the aromatic ring decrease Hb affinity
for O2 by binding strongly to deoxy-Hb and stabilize the T-state.142 Replacement of the
carboxylate with a methoxy group, such as in vanillin disrupts these intersubunit interactions in
the T-state, resulting in weak binding to the T-state structure but stronger binding to the R-state
structure, leading to left-shift of the OEC.118
Although the OEC results for these compounds are unexpected, because of the significant
right-shifting ability of TD-3, it could be potentially useful for the treatment of ischemic-related
diseases. Remarkably, it is as potent as RSR-13, which has been studied for several ischemicrelated diseases.14,143

B. Substitution of hydroxymethyl group on the pyridine ring of pyridyl derivatives of
benzaldehydes resulted in compounds that increase Hb oxygen affinity
As noted above, some INN compounds, such as INN-312 are known to bind to the α-cleft
of Hb and extend its pyridine-methoxy moiety (ortho to the aldehyde) toward the surface of the
protein.103 This leads to destabilization of polymer contacts in deoxy-Hb. Such molecules exhibit
dual anti-sickling activity; increasing Hb S O2 affinity, as well as preventing direct Hb S polymer
contact. Even though other INN compounds, such as INN-298, have the pyridine-methoxy
moiety (meta to the aldehyde) extended further down to the central water cavity,103 the added
hydrophobic/hydrogen-bond contacts with the protein due to the pyridine-methoxy moiety leads
to significant left-shifting potency. Based on this consideration, analogs of three INN compounds
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were prepared by adding hydroxymethyl moiety on the pyridine rings to obtain TD-7, TD-8 and
TD-9.
Expectedly, all three compounds resulted in left-shifting of the OEC in whole blood
(increase in Hb affinity for O2) amongst which TD-7 was found to be the most potent (-17.0
mmHg) at 2 mM, followed by TD-9 (-10.2 mmHg) and lastly TD-8 which showed a significantly
low left-shifting effect of -5.5 mmHg (Table 1). TD-7 was found to be more potent than the
positive control, 5HMF. The results also compare with the previously studied INN-312, INN-298
and INN-296 with ΔP50 of ~ -17, -14 and -16 mmHg, respectively at 2 mM drug concentration.119
It is obvious, however, that these three compounds may be equipotent (as observed) using cellfree Hb for the OEC study (Table 2). These results suggest that the presence of plasma proteins,
serum enzymes and RBC cell membrane do play an interfering role on the activity of the
compounds in whole blood. In the absence of these interfering components of the whole blood
(as in the case of cell-free Hb), the compounds directly act on the Hb molecule and cause an
effect, which can be seen by comparing the results of whole blood and cell-free Hb. Therefore,
the low biological activity of TD-8 and TD-9 could be attributed to plasma protein binding
and/or RBC membrane permeability. It has been previously studied that plasma or RBC
membrane does not interfere significantly with 5HMF, INN-312, INN-298 and INN-296 binding
to Hb.18,106
TD-7 also exhibits time-dependent allosteric profile in whole blood (Table 3, Figure 12).
From the previous concentration-dependent studies (Table 1), it was seen that 0.5 mM was the
lowest concentration at which TD-7 showed left-shifting activity. Thus, 0.5 mM concentration
was chosen for time-dependent studies. We observed extended left-shifting activity for TD-7
with no recovery even at 12 h. In contrast, 5HMF activity peaked between 2-6 h and began to
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recover to the baseline after 6 h. This suggests that it’s the sustained effect of TD-7 may provide
an advantage in chronic use in the prophylaxis of SCD crises. Our previous study with INN-298
and INN-312 also resulted in similar long duration effect.119
Compounds that increase the O2 affinity of Hb exhibit anti-sickling activity since the highO2-affinity Hb S does not polymerize.55-57 Therefore the effect of TD-7 on sickle RBC
morphology was studied by our collaborators, Drs. Asakura and Abdulmalik (CHOP). As
expected from its left-shifting ability, TD-7 also prevented sickling of RBC in a dose dependent
manner (Table 5 and Figure 14). As shown in Table 5, the anti-sickling effect of this compound
was found to be ~6-fold more effective than 5HMF and ~2-fold more effective than INN-312 at
1 mM concentration.103 It was observed that as the concentration of TD-7 was increased from
0.5 mM to 1 mM, a plateau effect was observed with 95% inhibition of sickling at both the
concentrations. On further concentration increase, complete inhibition (100% inhibition) was
observed. This remarkable increase in the anti-sickling activity is not explainable by the leftshifting ability alone, and it suggests an additional mode of anti-sickling effect, which possibly
could be due to Hb S polymer destabilization, as hypothesized. As compared to TD-7, the
positional isomers, TD-8 and TD-9, were seen to be ~5-fold and ~3-fold less effective antisickling agents respectively.
We co-crystallized TD-7 with deoxy-Hb to understand its mechanism of action. Our
study with TD-7 using high-salt condition resulted in both T-state and R-state crystals, however,
while the former crystals were big enough to diffract, the latter were too small for diffraction.
We are yet to collect data for any of these crystals. However, we determined the structure of the
T-state Hb in complex with TD-7 with crystals obtained with low-salt crystallization conditions.
We anticipate this structure to be similar to the structure from the high-salt crystal.
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The structure shows two molecules of TD-7 bound in a symmetry-related fashion at the
α-cleft of deoxy-Hb. Similar to other anti-sickling aromatic aldehydes, TD-7 is also weakly
bound.118 Nevertheless, the weak and broken density allows us to model the approximate
position of the bound compound, which shows the aldehyde making a Schiff base interaction
with the N-terminal amine of α1Val1. The hydroxymethyl-pyridine-methoxy substituent was
also seen to point upwards, towards the mouth of the central water cavity, as previously observed
with INN-312 where the pyridine-methoxy of INN-312 was observed to make close hydrophobic
contact with αPro77.106 αPro77, as well as the residues αVal73, Asp74, αAsp75, αMet76,
αPro77 and Asn78 are part of a helix (F-helix) located at the surface of the protein. The αF-helix
residue, Asn78 has been implicated in stabilizing the Hb S fiber, and the Hb variant, Stanleyville
(αAsn78 ↔ αLys78) is known to inhibit gelation.58 It was suggested that the contact between
INN-312 and the αF-helix led to destabilization of polymer contact between the Hb S molecules,
contributing to the significant anti-sickling activity of this compound, which was consistent with
solubility studies.106 The fact that the pyridyl moiety of TD-7 also points toward this helix
apparently making stronger hydrophobic interaction with Pro77 (Figure 16-18) could explain its
significant anti-sickling activity. More significantly, we also observe what appear to be watermediated interactions between the hydroxyl of TD-7 and several of the helix residues which
could even result in more polymer destabilization effect. Thus, the hydroxymethyl substituent we
propose is playing a critical role in the anti-sickling property of some of the effectors, especially
those that bind and extend outward toward the surface of the protein.
In conclusion, we have been able to design and synthesize several left-shifting agents, with at
least one of them exhibiting remarkable anti-sickling activity. Further studies, including
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solubility study, in vivo studies with sickle mice are ongoing by our collaborators at CHOP.
TD-8 and TD-9 are also currently being tested for their anti-sickling activities.

C. Nitrate esterification of anti-sickling aromatic aldehydes lead to compounds that
increase Hb oxygen affinity, as well as make NO bioavailable
Another reason for the synthesis of the hydroxymethyl analogs of INN compounds was to
afford us compounds to attach a nitrate ester moiety to the hydroxymethyl substituent. 5HMF
already had a hydroxymethyl moiety which was taken advantage for attaching a nitrate ester
moiety. Nitrate esters are easily prone to hydrolysis,144 therefore experiments were performed to
check the stability of the nitrate ester compounds. UPLC-MS was done on previously prepared
stock solutions of the nitrate ester compounds (TD-1, TD-7-1, TD-8-1 and TD-9-1). 100 µM
stock solutions were prepared in DMSO and stored for 3 months at −20°C during which time it
was exposed to at least 6 freeze-thaw cycles. It was observed that the compounds were stable,
suggesting no degradation, which provided evidence that the nitrate esters were intact and did
not hydrolyze to NO and the parent compound prior to OEC studies and Griess assay studies.
We hypothesize that in vivo the nitrate ester will be hydrolyzed to release NO to the
vasculature, while the parent aromatic aldehyde will bind to Hb, shift the OEC to the left to
increase the more soluble high-O2-affinity Hb fraction and thus prevent Hb S polymerization.
The ester nitrate analogs of 5HMF, TD-7, TD-8 and TD-9 were synthesized to give TD-1,
TD-7-1, TD-8-1 and TD-9-1 respectively.
The effects of the compounds on Hb affinity for oxygen using whole blood were also
studied (Tables 1 and Figure 11). Although the nitrate ester derivatives show left-shifting
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abilities, their potencies were less than the parent compounds, which could partly be due to
incomplete/slow nitrate ester hydrolysis and/or plasma protein binding and/or difficulties
associated with RBC membrane permeability. Studies were conducted using cell-free Hb as
shown in Table 2. It was seen that all the tested compounds, including the nitrate esters TD-7-1
and TD-1, showed weaker left-shifting potency as compared to their parent compounds TD-7
and 5HMF. This observation supports our hypothesis of incomplete/slow nitrate ester hydrolysis
and/or the interference of plasma proteins and RBC cell membrane with the biological activity of
the nitrate ester compounds. Studies on cell-free Hb with TD-8-1 and TD-9-1 are yet to be
performed to test if these compounds behave in a similar manner. Most likely the nitrate ester
derivatives did not completely hydrolyze to free the parent anti-sickling compound. Thus the
non-hydrolyzed compound binds and stabilizes the T-state as observed in the crystallographic
study for TD-1 (see below) to cancel out any anti-sickling effect of the free parent aromatic
aldehyde. This could pose a major problem for SCD treatment, unless in vivo, significant
hydrolysis could take place to free the parent compound.
Nonetheless, we note that the compounds are capable of hydrolyzing to release NO. Due
to the high reactivity of NO, extremely low concentrations (pM to nM range) are required for
biological activity such as anti-inflammatory, vasodilatory activity and prevention of platelet
aggregation.126 Nitric oxide release studies were performed on the nitrate ester derivatives; TD-1,
TD-7-1, TD-8-1 and TD-9-1 as shown in Table 4. It was observed that all the compounds
!
released the NO!
! in a time-dependent manner with TD-1 showing the least NO! release while

TD-8-1 showing maximum NO!
! release as compared to the other nitrate ester compounds. These
results suggest that the nitrate ester compounds have a potential of hydrolyzing and releasing NO
to the vasculature, although the extent of the release is not clear without doing in vivo animal
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studies. Such studies are planned in the future. Nevertheless, it is obvious that whether NO is
released or the nitrate ester is intact, the compounds are able to maintain their left-shifting
anti-sickling activities.
Another significant observation is that the nitrate ester derivative of TD-7 (TD-7-1)
resulted in significant hemolysis of the RBC, which could pose toxicity problem. The reason
behind this behavior is unclear, but further studies are ongoing to determine the cause, as we do
not see the same effect with TD-1.
We also determined the crystal structure of TD-1 (nitrate ester derivative of 5HMF) in
complex with deoxy-Hb to explain its weak allosteric and anti-sickling activity. The initial
electron density map showed two molecules of TD-1 forming Schiff base interaction with αVal1
amino group of both α-subunits at the α-cleft in a symmetry-related fashion (Figures 19 and 20).
Unlike TD-7, the ligand density of TD-1 was very strong and well defined, allowing
unambiguous fitting of the ligand into the density for subsequent refinement. This is in contrast
with 5HMF, which like all left-shifters binds weakly to T-state Hb.118 The increased number of
interactions (Figure 21) including inter-subunit water-mediated hydrogen bonds with α2Ser138
and α2Arg141 and interactions with water molecules, serve to tie the α1 and α2 subunits together
and stabilize the T-state Hb on TD-1 binding. The fact that most of the bound compound is the
nitrate ester analog which apparently is stabilizing the T-state structure is consistent with the
functional/biological studies that show weak left-shifting and/or anti-sickling effect of this
compound. Thus, for this compound to be an effective anti-sickling agent, it must release the NO
prior to binding to Hb and not bind as the nitrate ester. It is anticipated that this would occur in
vivo, and plans are underway to test this compound in mice.

92	
  
	
  

	
  
	
  

2. Allosteric effectors of Hb that decrease the oxygen affinity of Hb with the capability of
releasing NO
The discovery that 2,3-DPG decreases the O2 affinity of Hb to allow efficient release of
O2 to tissues prompted the search for synthetic Hb effectors that act similarly to 2,3-DPG but are
more potent and orally bioavailable for therapeutic purposes. Even as much as a 2 mmHg shift
(in P50) in the OEC may represent a beneficial response that increases O2 delivery.14 This has
culminated in the discovery of several aromatic propionates, including RSR-13 and several of it
analogs.112
RSR-13 is a potent Hb effector, which increases the O2 releasing capacity by decreasing
Hb affinity for O2. It thus shifts the OEC curve to the right and stabilizes the T-state Hb. RSR-13
was being studied in the phase III clinical trials as a radio-sensitizing agent,145 due to its property
of releasing O2 to tumorous tissues. A potential problem with the use of right-shifting agent is
excessive tissue oxygenation that induces vasoconstriction.131 Therefore; a right-shifting agent
with the ability to release NO could potentially mitigate the problem of vasoconstriction by its
vasodilatory property. The nitrate ester analog of RSR-13 was synthesized so as to perform as a
dual acting agent, which delivers O2 to the tissues as well as releases NO to the vasculature.
UPLC-MS analysis showed the nitrate ester to be stable in solution.
The study with RSR-13 and DD-1 showed both compounds to shift the OEC to the right
as previously observed for RSR-13.112 Time-dependent studies performed on DD-1 and RSR-13
(Table 8) suggested that the P50 values of both compounds, increased consistently with time
(Figure 22). Initially, P50 value of DD-1 was lower than that of the parent compound but as the
incubation time crossed 4 h, the P50 value of DD-1 was seen to increase over the parent
compound. Based on these results, it can be interpreted that the nitrate ester analog, DD-1, has a
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better O2 releasing capacity as compared to RSR-13 after 4 h, and possibly it is a slow binder
compared to RSR-13.
During the NO release studies performed with DD-1 (Table 9), it was observed that,
unexpectedly, the NO!
! release for 1 h was around 2-fold greater than the release after 16 h.
Although it did show some NO!
!   release, it was not as much as that seen for the left-shifting
nitrate ester compounds. This suggests that the compound has a potential of releasing NO to the
vasculature, although the extent of the release is not clear, without doing in vivo studies. Such
studies are planned in the future. Nevertheless, it is obvious that whether that NO is released or
the nitrate ester is intact, the compound is able to significantly decrease Hb affinity for oxygen.
To understand the mechanism of action of DD-1, we co-crystallized deoxy-Hb with
DD-1. The electron density map showed a mixture of two well defined densities of bound
DD-1/RSR-13 molecules in a symmetry-related manner at the middle of the central water cavity
(Figures 23 and 24); similar to what was previously observed for RSR-13,28 except for additional
interactions by the nitrate ester moiety. Relatively, weak electron density was observed for the
nitrooxyethylene moiety of the DD-1. The direct contacts as well as water-mediated interactions
formed by each DD-1/RSR-13 molecule with 3 subunits, 2 α-subunits and 1 β-subunit, stabilize
the T-state as noted in the result section. Additional interactions between the nitrooxyethylene
moiety and the T-state Hb residues, lead to further stabilization of the T-state, which may explain
the significant potency of DD-1 over RSR-13. This observation could help in explaining the
OEC results, suggesting that hydrolyzed RSR-13 binds first to the Hb while binding of the nitrate
ester derivative occurs later. Similar interactions are observed for DD-1 as previously observed
for RSR-13.28 Interactions between αLys99 and carbonyl oxygen, and 3,5-dimethyl benzene
interaction with the amide group of βAsn108, are essential for activity since these interactions
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stabilize T-state Hb.28 Similar to RSR-13 binding, the methyl propionic acid moiety participates
in water-mediated interactions with the side chain guanidinium of αArg141, which also
constrains the T-state.28 The oxygen adjacent to the carbonyl group is also shown to form watermediated hydrogen bond interaction with the hydroxyl of α1Thr134. There are several watermediated interactions between the amide nitrogen of DD-1/RSR-13 and surrounding protein
residues that contribute in stabilizing the T-state.
The nitrate group is involved in direct hydrogen bond and water-mediated interactions
with α1Thr134, α1Ser131, and α1Val1 as shown in Figures 25 and 26. These interactions add
additional constraint to and stabilize the T-state Hb. Irrespective of whether the compound is the
hydrolyzed RSR-13 or the non-hydrolyzed DD-1, it binds to the T-state Hb in a similar fashion
so as to stabilize the T-state, which can be correlated with the OEC studies suggesting a similar
right-shift (O2 releasing property) for both RSR-13 and DD-1 molecules.
In addition to the DD-1/RSR-13 binding, we also observed a bound 2,3-DPG molecule at
the β-cleft of Hb (Figure 24), which most likely leads to further stabilization of the T-state Hb.
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CONCLUSIONS

This project was focused on two objectives which included the synthesis, testing and structural
studies of (1) Allosteric effectors of Hb (AEH) that increase the O2 affinity of Hb (left-shifting of
the OEC) with or without the capability of releasing NO and (2) AEHs that not only decrease the
O2 affinity of Hb (right-shifting of the OEC) but are also capable of releasing NO. The former
compounds are being developed for treating SCD, while the latter for ischemic-related diseases.
Under hypoxic conditions, Hb S undergoes intracellular polymerization to form
polymerized fibers, which increases rigidity and decreases flexibility of the RBCs.117 Sickled
RBCs are fragile and are prone to rupture or lysis to release free plasma Hb, a potent NO
scavenger.44 Developing means to modify Hb S from low O2 affinity Hb to high O2 affinity Hb
would help in preventing polymerization of Hb S and be beneficial in treating the complications
of SCD.103,107,118 Moreover, delivering NO exogenously for therapeutic purposes or to enhance
its endogenous production, would be highly effective in targeting the ramifications of NO
deficiency.121 Therefore, development of AEHs which would increase the Hb O2 affinity and/or
release NO was one of the objectives of this project.
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Towards this objective, we synthesized 9 compounds, all analogs of the previously
studied anti-sickling 5HMF and INN compounds that we proposed would bind to R-state Hb and
increase its O2 affinity. Some of the compounds, especially those with the hydroxymethyl
substituent on the pyridine ring showed left-shifting properties as predicted, with one of the
compounds, TD-7, showing a remarkable anti-sickling effect, ~6-fold and ~2-fold more effective
than 5HMF and INN-312 respectively, at the same concentration of 1 mM. Although more
studies need to be performed to completely unravel TD-7’s anti-sickling mechanism, it is likely
that in addition to it’s ability to increase the oxygen-affinity of Hb due to stabilization of the
R-state Hb, it may also destabilize polymer contacts due to the extended hydroxymethylpyridine-methoxy group directed towards the surface of the protein. Therefore TD-7 provides a
new structural scaffold for further drug development for SCD.
Two of the synthesized compounds, TD-2 and TD-3, were proposed to left-shift the OEC
and increase the O2 affinity of Hb by making hydrogen bonding interactions with the R-state Hb.
However, TD-3 instead of increasing Hb affinity for oxygen, unexpectedly resulted in the
opposite effect. It is possible the amide analog (TD-3) binds strongly to deoxy-Hb and stabilize
the T-state Hb, leading to a shift in the allosteric equilibrium to the low O2 affinity Hb.
Nevertheless, TD-3 could potentially be developed for the treatment of ischemic-related
diseases. The ester analog, TD-2, was found to be inactive and did not affect the oxygen affinity
of Hb. The inactivity of TD-2 could be probably attributed to aldehyde dehydrogenase (ALDH)
metabolism or metabolism by esterases inside the RBCs that cleave or metabolize the ester
linkage and inactivate it.
Based on the fact that SCD is characterized by NO deficiency; as a result of scavenging
by free Hb,44 we decided to derivatize some of the above compounds with nitrate esters, to
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produce TD-1, TD-7-1, TD-8-1 and TD-9-1. These compounds are proposed to hydrolyze in vivo
to make NO bioavailable to the vasculature, consistent with our in vitro study135 that show the
release of NO in the presence of L-cysteine. It is also anticipated that the released aromatic
aldehyde would bind to Hb S and left shift the OEC to increase the O2 affinity and hence the
solubility of Hb S to prevent sickling.
Several AEHs, such as RSR-13 that bind to Hb and decrease its oxygen affinity have
been studied for use in ischemic-related diseases15,113 and as a radio-sensitizing agent.145 A
potential problem in the use of these AEHs is the excessive tissue oxygenation which could
induce vasoconstriction.130 A right-shifting agent with the ability to release NO could potentially
mitigate this problem by its property of vasodilation. Therefore we synthesized the nitrate ester
analog of RSR-13 (DD-1) to study both its right-shifting property as well as its potential to
deliver NO to the vasculature. Not only did the compound show significant right-shifting
activity, it also showed the release of NO, although not quite significantly, thus providing a
potential dual-acting agent, which could be beneficial in the treatment of ischemia. However, it
is also anticipated that more NO will be released in vivo.
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EXPERIMENTAL

1. Chemistry:
General Information: Melting points were determined on a Fisher-Scientific melting point
apparatus and were uncorrected. 1H-NMR and

13

C-NMR spectras were obtained on a Brucker

400 MHz spectrometer and tetramethylsilane (TMS) was used as an internal standard. Peak
positions are given in parts per million (δ). Column chromatography was performed on silica gel
(grade 60 mesh; Bodman Industries, Aston, PA). Routine thin-layer chromatography (TLC) was
performed on silica gel GHIF plates (250 µm, 2.5 x 10 cm; Analtech Inc., Newark, DE).
UHPLC-MS was recorded on a Perkin Elmer Flexar UHLPC with AxION 2 Time of Flight
(TOF) Mass Spectrometer and the molecular weight of the compounds was within 0.05% of
calculated values. Elemental analysis was performed by Atlantic Microlab Inc. (Norcross, GA)
for the elements indicated and the results are within 0.4% of calculated values. Infrared spectra
were obtained on a Thermo Nicolet iS10 FT-IR. Purity of the compounds was determined by
HPLC using a Varian Microsorb 100-5 C18 column (250 x 4.6 mm), using Prostar 325 UV-Vis
(254 nm) as the detector.
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2-Formyl-4-methoxyphenyl isonicotinate (TD-2 or 35):

Compound TD-2 (35) was prepared according to literature procedure for a similar compound.146
Isonicotinylchloride hydrochloride (47) (0.35 g, 2.0 mmol) was added to a solution of 2hydroxy-5-methoxybenzaldehyde (46) (0.2 g, 1.3 mmol) in pyridine (10 mL) at 0 °C (ice-bath).
The reaction mixture was allowed to stir at 50 °C for 2 h, diluted with CH2Cl2 (15 mL) and the
solvent was evaporated under reduced pressure to yield a crude residue which was dissolved in
CH2Cl2 (20 mL), washed with brine (2 x 10 mL), dried over Na2SO4 and evaporated to dryness
under reduced pressure to yield a crude product, which was further purified by column
chromatography (petroleum ether/EtOAc; 3:1), to yield 0.04g (12%) of 35 as a white-colored
solid: mp 127-128 °C; IR (KBr, cm-1): 1733 (C=O); 1H-NMR (CDCl3): δ 3.89 (s, 3H, OCH3),
7.22-7.23 (m, 2H, ArH), 7.41-7.42 (m, 1H, ArH), 8.01-8.03 (dd, J = 4.4, 1.6 Hz, 2H, ArH),
8.88-8.89 (dd, J = 4.6, 1.4 Hz, 2H, ArH), 10.10 (s, 1H, CHO);

13

C-NMR (CDCl3): δ 187.9,

164.0, 158.0, 150.94, 144.9, 136.17, 128.45, 124.3, 123.24, 121.9, 114.0, 55.92. MS (ESI) m/z
found 258.08 (M + H)+. The purity of the compound was checked by HPLC and was found to be
97.8% pure.
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N-(2-Formyl-4-methoxyphenyl) isonicotinamide (TD-3 or 36):

Compound TD-3 (36) was prepared according to literature procedure of a similar compound.146
Pyridine (0.12 mL, 1.45 mmol) was added to a solution of 2-amino-5-methoxybenzaldehyde (50)
(0.15 g, 0.50 mmol) in anhydrous CH2Cl2 (20 mL). Isonicotinylchloride HCl (47) (0.26 g, 1.45
mmol) was added and the reaction mixture was allowed to stir overnight at room temperature.
The reaction mixture was diluted with CH2Cl2 (15 mL) and the solvent was evaporated under
reduced pressure to yield a crude residue which was dissolved in CH2Cl2 (20 mL), washed with
brine (2 x 10 mL), dried over Na2SO4 and evaporated to dryness under reduced pressure to yield
a crude residue. The residue was purified by column chromatography (petroleum ether/EtOAc;
3:1) to yield 0.04g (31%) of 36 as a yellow-colored solid: mp 165-166 °C; IR (KBr, cm-1): 3014
(aromatic CH), 1686 (C=O), 1661 (NH-C=O); 1H-NMR (CDCl3): δ 3.90 (s, 3H, OCH3), 7.87 –
7.89 (dd, J = 4.5, 1.6 Hz, 2H, ArH), 8.84 - 8.87 (m, 3H, ArH), 9.98 (s, 1H, NH), 11.95 (s, 1H,
CHO);

13

C-NMR (CDCl3): δ 195.71, 163.7, 155.79, 150.94, 150,94, 141.54, 134.14, 123.06,

122.26, 121.89, 120.10, 117.2, 55.83. MS (ESI) m/z found 257.10 (M + H)+. The purity of the
compound was checked by HPLC and was found to be 99.5% pure.
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2-((6-(Hydroxymethyl)pyridin-2-yl)methoxy)-5-methoxybenzaldehyde (TD-7 or 37):

Compound TD-7 (37) was prepared according to literature procedure for a similar compound.103
A mixture of 2-hydroxy-5-methoxybenzaldehyde (46) (0.20 mL, 1.5 mmol), 6-(bromomethyl)-2pyridinemethanol (51) (0.30 g, 1.5 mmol), and K2CO3 (0.25 g, 1.8 mmol) in anhydrous DMF (20
mL) was allowed to stir at room temperature for 12 h. The reaction mixture was diluted with
EtOAc (20 mL), washed with H2O (2 x 20 mL), brine (2 x 10mL), dried over Na2SO4 and
evaporated under reduced pressure to yield a crude product. The residue was purified by column
chromatography (petroleum ether/EtOAc; 1:1) to yield 0.32g (78%) of 37 as a yellow-colored
solid: mp 84-85 °C; IR (KBr, cm-1): 3396 (O-H), 1678 (C=O); 1H-NMR (CDCl3): δ 3.51 (s, 1H,
OH), 3.81 (s, 3H, OCH3), 4.79 (s, 2H, CH2), 5.29 (s, 2H, CH2), 6.99 (d, J = 9.0 Hz, 1H, ArH),
7.09-7.13 (dd, J = 9.0, 3.2 Hz, 1H, ArH), 7.21 (d, J = 7.7 Hz, 1H, ArH), 7.37 (d, J = 3.2 Hz, 1H,
ArH), 7.43 (d, J = 7.6 Hz, 1H, ArH), 7.74 (t, 1H, ArH), 10.58 (s, 1H, CHO); 13C-NMR (CDCl3):
δ 189.24, 158.80, 155.61, 154.17, 154.17, 137.66, 125.56, 123.40, 119.84, 119.64, 114.92,
110.917, 71.65, 64.02, 55.86. MS (ESI) m/z found 274.15 (M + H)+, 296.14 (M + Na)+. The
purity of the compound was checked by HPLC and was found to be 97.8% pure.
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2-((6-(Hydroxymethyl)pyridin-2-yl)methoxy)-4-methoxybenzaldehyde (TD-9 or 38):

Compound TD-9 (38) was prepared according to literature procedure for a similar compound.103
A mixture of 2-hydroxy-4-methoxybenzaldehyde (52) (113 mg, 0.74 mmol), 6-(bromomethyl)-2pyridinemethanol (51) (150 mg, 0.74 mmol), and K2CO3 (123 mg, 0.90 mmol) in anhydrous
DMF (20 mL) was stirred at room temperature for 12 h. The reaction mixture was diluted with
EtOAc (20 mL), washed with H2O (2 x 20 mL), brine (2 x 10mL), dried over Na2SO4 and
evaporated under reduced pressure to yield a crude product. The crude was purified by column
chromatography (petroleum ether/EtOAc; 1:1) to yield 190 mg (94%) of 38 as a yellow-colored
solid: mp 104-105 °C; IR (KBr, cm-1): 3153 (O-H), 1599 (C=O); 1H-NMR (CDCl3): δ 3.58 (s,
1H, OH), 3.85 (s, 3H, OCH3), 4.78 (d, 2H, CH2), 5.30 (s, 2H, CH2), 6.53 (d, J = 2.2 Hz, 1H,
ArH), 6.60 (d, J = 2.16 Hz, 1H, ArH), 7.22 (d, J = 7.68 Hz, 2H, ArH), 7.47 (d, J = 7.76 Hz, 2H,
ArH), 7.76 (t, 1H, ArH), 7.85 (d, J = 8.64 Hz, 1H, ArH), 10.43 (s, 1H, CHO);

13

C-NMR

(CDCl3): δ 166.16, 162.27, 158.67, 155.51, 137.74, 131.04, 119.85, 119.69, 118.1, 106.68,
99.16, 70.85, 63.87, 55.66. MS (ESI) m/z found 274.11 (M + H)+, 296.09 (M + Na)+. The purity
of the compound was checked by HPLC and was found to be 96.9% pure.
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3-((6-(Hydroxymethyl)pyridine-2-yl)methoxy)-4-methoxybenzaldehyde (TD-8 or 39):

Compound TD-8 (39) was prepared according to literature procedure for a similar compound.103
A mixture of 3-hydroxy-4-methoxybenzaldehyde (53) (200 mg, 1.0 mmol), 6-(bromomethyl)-2pyridinemethanol (51) (152 mg, 1.0 mmol), and potassium carbonate (165 mg, 1.2 mmol) in
anhydrous DMF (20 mL) was stirred at room temperature for 12 h. The reaction mixture was
diluted with EtOAc (20 mL), washed with H2O (2 x 20 mL), brine (2 x 10mL), dried over
Na2SO4 and evaporated under reduced pressure to yield a crude product. The crude was purified
by column chromatography (petroleum ether/EtOAc; 1:1) to yield 220 mg (80%) of 39 as a
white-colored solid: mp 120-121 °C; IR (KBr, cm-1): 3176 (O-H), 1681 (C=O); 1H-NMR
(CDCl3): δ 3.65 (s, 1H, OH), 4.00 (s, 3H, OCH3), 4.78 (d, 2H, CH2), 5.32 (d, 2H, CH2), 7.03 (d,
J = 8.72 Hz, 1H, ArH), 7.17 (d, J = 7.68 Hz, 1H, ArH), 7.44-7.51 (m, 3H, ArH), 7.71 (t, 1H,
ArH);

13

C-NMR (CDCl3): δ 190.66, 155.53, 154.95, 137.54, 130.11, 126.88, 119.99, 119.60,

111.92, 110.98, 158.79, 71.40, 63.90, 56.22. MS (ESI) m/z found 274.11 (M + H)+, 296.09 (M +
Na)+. The purity of the compound was checked by HPLC and was found to be 99.5% pure.
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5-Nitrooxymethyl furfural (TD-1 or 40):

Compound TD-1 (40) was prepared according to literature procedure for a similar compound.147
Trifluoroacetic anhydride (5.5 mL, 2 mmol) was added to a suspension of lithium nitrate (2.7 g,
2 mmol) in anhydrous CH3CN (30 mL) at 20 °C. The reaction mixture was stirred until clear (30
min) and cooled to 0 °C (ice-bath). Sodium carbonate (4.2 g, 2 mmol) and 5-hydroxymethyl-2furfural (27) (2.5 g, 1 mmol) were added together and the reaction mixture was allowed to stirred
for 7 h at 0 °C (ice-bath). The reaction mixture was poured into an ice-cold solution of saturated
NaHCO3 and extracted with EtOAc (2 x 10 mL). The combined organic portion was washed
with brine (10 mL), dried over Na2SO4 and evaporated under reduced pressure to yield a crude
product. The crude residue was purified by column chromatography (petroleum ether/EtOAc;
2:1) to afford 2.9 g (85%) of 40 as a colorless viscous oil: IR (KBr, cm-1): 1678 (C=O), 1631,
1276 (NO2), 845 (ON); 1H-NMR (CDCl3): δ 5.48 (s, 2H, CH2), 6.73 (d, J = 3.5 Hz, 1H, ArH),
7.25 (d, J = 3.6, 1H, ArH), 9.68 (s, 1H, CHO); 13C-NMR (CDCl3): δ 177.9, 153.4, 151.5, 120.9,
114.5, 65.4. Anal. Calcd for (C6H5NO5) C, 42.12; H, 2.95; N, 8.19. Found: C, 42.02; H, 2.86; N,
8.26. The purity of the compound was checked by HPLC and was found to be 98.8% pure.
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(6-((2-Formyl-4-methoxyphenoxy)methyl)pyridin-2-yl)methyl nitrate (TD-7-1 or 41)

Compound TD-7-1 (41) was prepared according to literature procedure for a similar
compound.148 Silver nitrate (76 mg, 0.45 mmol) was added to a solution of 2-((6(bromomethyl)pyridin-2-yl)methoxy)-5-methoxybenzaldehyde (54) (100 mg, 0.3 mmol) in
anhydrous CH3CN (5 mL). The reaction mixture was allowed to stir at 80 °C for 2 h. The
reaction mixture was ﬁltered through celite and washed with CH2Cl2 (15 mL), and evaporated
under reduced pressure to yield a crude product. The crude residue was puriﬁed by column
chromatography (petroleum ether/EtOAc; 5:1) to yield 80 mg (83.78%) of 41 as a white-colored
solid: mp 92-93 °C; IR (KBr, cm-1): 1664 (C=O), 1632 (NO2), 1274 (NO2), 872 (ON); 1H-NMR
(CDCl3): δ 3.81 (s, 3H, OCH3), 5.28 (d, 2H, CH2), 5.56 (s, 2H, CH2), 6.98 (d, J = 9.08Hz, 1H,
ArH), 7.10-7.13 (dd, J = 9.08, 3.28 Hz, 1H, ArH), 7.33-7.37 (dd, J = 8.4, 3.24 Hz, 2H, ArH),
7.53 (d, J = 7.84 Hz, 1H, ArH), 7.80 (t, 1H, ArH), 10.57 (s, 1H, CHO);

13

C-NMR (CDCl3): δ

189.18, 157.08, 155.20, 154.20, 152.50, 138.05, 125.52, 123.38, 121.27, 121.19, 114.85, 111.00,
74.15, 71.51, 55.85. MS (ESI) m/z found 319.09 (M + H)+, 341.07 (M + Na)+. The purity of the
compound was checked by HPLC and was found to be 94.5% pure.
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(6-((2-Formyl-5-methoxyphenoxy)methyl)pyridin-2-yl)methyl nitrate (TD-9-1 or 42)

Compound TD-9-1 (42) was prepared according to literature procedure for a similar
compound.148 Silver nitrate (76 mg, 0.5 mmol) was added to a solution of 2-((6(bromomethyl)pyridin-2-yl)methoxy)-4-methoxybenzaldehyde (55) (100 mg, 0.3 mmol) in
anhydrous CH3CN (5 mL). The reaction mixture was allowed to stir at 80 °C for 2 h. The
reaction mixture was ﬁltered through celite and washed with CH2Cl2 (15 mL) and evaporated
under reduced pressure to yield a crude product. The crude product was puriﬁed by column
chromatography (petroleum ether/EtOAc; 5:1) to yield 53 mg (56%) of 42 as a white – colored
solid: mp 70-71 °C; IR (KBr, cm-1): 1677 (C=O), 1285 (NO2), 871 (ON); 1H-NMR (CDCl3-d1): δ
3.85 (s, 3H, OCH3), 5.29 (s, 2H, CH2), 5.56 (s, 2H, CH2), 6.52 (d, J = 2.16 Hz, 1H, ArH), 6.586.61 (m, 1H, ArH), 7.34 (d, J = 7.68 Hz, 1H, ArH), 7.58 (d, J = 7.88 Hz, 1H, ArH), 7.79-7.85
(m, 2H, ArH), 10.42 (s, 1H, CHO);

13

C-NMR (CDCl3): δ 166.19, 163.05, 158.71, 155.53,

138.15, 131.18, 121.31, 121.28, 118.15, 106.95, 99.07, 74.14, 70.80, 55.68. MS (ESI) m/z found
341.08 (M + Na)+. The purity of the compound was checked by HPLC and was found to be
99.8% pure.
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(6-((5-Formyl-2-methoxyphenoxy)methyl)pyridin-2-yl)methyl nitrate (TD-8-1 or 43)

Compound TD-8-1 (43) was prepared according to literature procedure for a similar
compound.148 Silver nitrate (76 mg, 0.45 mmol) was added to a solution of 3-((6(bromomethyl)pyridine-2-yl)methoxy)-4-methoxybenzaldehyde (56) (100 mg, 0.3 mmol) in
anhydrous CH3CN (5 mL). The reaction mixture was allowed to stir at 80 °C for 2 h. The
reaction mixture was ﬁltered through celite and washed with CH2Cl2 (15 mL) and evaporated
under reduced pressure to yield a crude product. The crude was puriﬁed by column
chromatography (petroleum ether/EtOAc; 5:1) to yield 94 mg (98%) of 43 as a yellow-colored
solid: mp 43-44 °C; IR (KBr, cm-1): 1683 (C=O), 1632 (NO2), 850 (ON); 1H-NMR (CDCl3): δ
3.99 (s, 3H, OCH3), 5.31 (s, 2H, CH2), 5.57 (s, 2H, CH2), 7.02 (d, J = 8.24 Hz, 1H, ArH), 7.31
(d, J = 7.68 Hz, 1H, ArH), 7.46 (d, J = 2.16 Hz, 1H, ArH), 7.49-7.52 (dd, J = 8.2, 1.76 Hz, 1H,
ArH), 7.55 (d, J = 7.76 Hz, 1H, ArH), 9.82 (s, 1H, CHO); 13C-NMR (CDCl3): δ 190.56, 157.157,
155.01, 152.01, 152.47, 148.42, 137.91, 130.20, 126.78, 121.34, 121.00, 112.24, 111.08, 74.27,
71.43, 56.24. MS (ESI) m/z found 341.08 (M + Na)+. The purity of the compound was checked
by HPLC and was found to be 96.9% pure.
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2-(Nitrooxy)ethyl 2-(4-(2-((3,5-dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2methylpropanoate (DD-1 or 44):

Compound DD-1 (44) was prepared according to literature procedure for a similar compound.103
RSR-13 (5.8 g, 17 mmol) (30) and K2CO3 (5.5 g, 40 mmol) were added to a solution of 2bromoethyl nitrate (58) in anhydrous DMF (40 mL). The reaction mixture was allowed to stir for
24 h at room temperature, was diluted with EtOAc (150 mL), washed with H2O (3 x 40 mL),
dried over MgSO4 and evaporated under reduced pressure to give a crude product. The crude
residue was purified by column chromatography (petroleum ether/EtOAc; 2:1) to yield 7.12g
(97.4%) of 44 as a white-colored solid: mp 74-75 °C; IR (KBr, cm-1): 1741 (C=O), 1379 (NO),
1276 (NO2), 1143 (CO), 845 (ON); 1H-NMR (CDCl3): δ 1.63 (s, 6H, CH3), 2.26 (s, 6H, CH3),
3.48 (d, J = 4.8 Hz, 2H, CH2), 3.64 (s, 2H, CH2), 4.09-4.15 (dd, J = 14.32, 7.16 Hz, 2H, CH2),
5.29 (s, 1H, NH), 6.73 (s, 1H, ArH), 6.86 (d, J = 8.52 Hz, 2H, ArH), 7.04 (s, 2H, ArH), 7.19 (d, J
= 8.52 Hz, 2H, ArH);

13

C-NMR (CDCl3): δ 173.83, 169.04, 154.74, 138.64, 138.64, 137.48,

130.39, 10.39, 128.40, 126.15, 119.69, 119.69, 117.54, 117.54, 30.03, 60.96, 4.09, 25.38, 25.38,
21.26, 21.26. MS (ESI) m/z found 431.18 (M + H)+. The purity of the compound was checked by
HPLC and was found to be 97.3% pure.
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5-Methoxy-2-nitrobenzaldehyde (49):

Compound 49 was prepared as described.149 Methyl iodide (0.41 mL, 6.5 mmol) was added in a
drop wise manner to a suspension of 5-hydroxy-2-nitrobenzaldehyde (1.0 g, 6.0 mmol) (48) and
K2CO3 (0.83 g, 6.0 mmol) in anhydrous DMF (20 mL) at 0 °C (ice-bath) and the reaction
mixture was allowed to stir at room temperature for 12 h. The reaction mixture was filtered and
the filtrate was diluted with CH2Cl2 (10 mL), evaporated under reduced pressure to yield a crude
residue, dissolved in EtOAc (20 mL), washed with H2O (2 x 10 mL), brine (2 x 10 mL), dried
over Na2SO4 and evaporated to dryness under reduced pressure to yield a crude residue which
upon recrystallization using petroleum ether/EtOAc yielded 1.02g (94%) of 49 as an off-white
colored solid: mp 80-81 °C (lit150 mp 81-82 °C); 1H-NMR (CDCl3): δ 3.96 (s, 3H, OCH3), 7.147.17 (dd, J = 9.0, 2.8 Hz, 1H, ArH), 7.34 (d, J = 2.8 Hz, 1H, ArH), 8.17 (d, J = 9.0 Hz, 1H,
ArH), 10.49 (s, 1H, CHO).

2-Amino-5-methoxybenzaldehyde (50):

Compound 50 was prepared as described.151 5-Methoxy-2-nitrobenzaldehyde (0.15 g, 0.8 mmol)
(49), iron powder (0.46 mg, 8.3 mmol), and conc. HCl (2 drops), were added to EtOH/H2O (4:1,
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5 mL) and the reaction mixture was allowed to stir at 95 °C for 2 h. The reaction mixture was
filtered, diluted with water (10 mL) and extracted with EtOAc (3 x 10mL). The combined
organic portion was washed with saturated NaHCO3 (2 x 10mL), H2O (2 x 10 mL), dried over
Na2SO4 and evaporated under reduced pressure to yield a crude product. The crude was then
purified by column chromatography (petroleum ether/EtOAc; 20:1) to yield 0.02 g (16.5%) of 50
as a yellow oil: 1H-NMR (CDCl3): δ 3.79 (s, 3H, OCH3), 5.83 (s, 2H, NH2), 6.62 (d, J = 8.8 Hz,
1H, ArH), 6.96 – 7.02 (m, 2H, ArH), 9.85 (s, 1H, CHO). The following compound was used for
the synthesis of TD-3 (36).

2-((6-(bromomethyl)pyridin-2-yl)methoxy)-5-methoxybenzaldehyde (54):

Compound 54 was prepared according to literature procedure for a similar compound.148
Triphenylphosphine (140 mg, 0.6 mmol) and tetrabromomethane (180 mg, 0.6 mmol) was added
to a solution of 2-((6-(hydroxymethyl)pyridin-2-yl)methoxy)-5-methoxybenzaldehyde (100 mg,
0.4 mmol) (37) in anhydrous CH2Cl2 (6 mL). The reaction mixture was allowed to stir for 2 h at
room temperature. The reaction mixture was neutralized with saturated NaHCO3 at 0 °C (icebath) and extracted with EtOAc (10 mL). The organic portion was washed with brine (2 x 10
mL), dried over Na2SO4 and evaporated under reduced pressure to yield a crude product. The
crude was puriﬁed by column chromatography (petroleum ether/EtOAc; 5:1) to yield 100 mg
(74.6%) of 54 as a yellow – colored solid: 1H-NMR (CDCl3): δ 3.81 (s, 3H, OCH3), 4.56 (s, 2H,
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CH2), 5.28 (d, 2H, CH2), 6.98 (d, J = 9.08 Hz, 1H, ArH), 7.10 – 7.13 (dd, J = 9.08, 3.28 Hz, 1H,
ArH), 7.33 – 7.37 (dd, J = 8.4, 3.24 Hz, 2H, ArH), 7.53 (d, J = 7.84 Hz, 1H, ArH), 7.80 (t, 1H,
ArH), 10.58 (s, 1H, CHO). The following compound was used for the synthesis of TD-7-1 (41).

2-((6-(bromomethyl)pyridin-2-yl)methoxy)-4-methoxybenzaldehyde (55):

Compound 55 was prepared according to literature procedure for a similar procedure.148
Triphenylphosphine (140 mg, 0.6 mmol) and tetrabromomethane (180 mg, 0.6 mmol) was added
to a solution of 2-((6-(hydroxymethyl)pyridin-2-yl)methoxy)-4-methoxybenzaldehyde (100 mg,
0.4 mmol) (38) in anhydrous CH2Cl2 (6 mL). The mixture was allowed to stir for 2 h at room
temperature. The reaction mixture was neutralized with saturated NaHCO3 at 0 °C (ice-bath) and
extracted with EtOAc (10 mL). The organic portion was washed with brine (2 x 10 mL), dried
over Na2SO4 and evaporated under reduced pressure to yield a crude product. The product was
puriﬁed by column chromatography (petroleum ether/EtOAc; 5:1) to yield 100 mg (75%) of 55
as a yellow-colored solid: 1H-NMR (CDCl3): δ 3.85 (s, 3H, OCH3), 4.56 (s, 2H, CH2), 5.30 (s,
2H, CH2), 6.53 (d, J = 2.16 Hz, 1H, ArH), 6.57-6.59 (m, 1H, ArH), 7.40 (d, J = 7.72 Hz, 1H,
ArH), 7.50 (d, J = 7.8 Hz, 1H, ArH), 7.76 (t, 1H, ArH), 7.84 (t, J = 8.68 Hz, 1H, ArH), 10.43 (s,
1H, CHO). The following compound was used for the synthesis of TD-9-1 (42).
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3-((6-(Bromomethyl)pyridine-2-yl)methoxy)-4-methoxybenzaldehyde (56):

Compound 56 was prepared according to literature procedure for a similar compound.148
Triphenylphosphine (140 mg, 0.6 mmol) and tetrabromomethane (180 mg, 0.6 mmol) was added
to a solution of 3-((6-(hydroxymethyl)pyridine-2-yl)methoxy)-4-methoxybenzaldehyde (100 mg,
0.4 mmol) (39) in anhydrous CH2Cl2 (6 mL). The mixture was allowed to stir for 2 h at room
temperature. The reaction mixture was neutralized with saturated NaHCO3 at 0 °C (ice-bath) and
extracted with EtOAc (10 mL). The organic portion was washed with brine (2 x 10 mL), dried
over Na2SO4 and evaporated under reduced pressure to yield a crude product. The crude was
puriﬁed by column chromatography (petroleum ether/EtOAc; 5:1) to yield 76 mg (56.5%) of 56
as a yellow-colored solid: 1H-NMR (CDCl3-d1): δ 3.99 (s, 3H, OCH3), 4.56 (s, 2H, CH2), 5.31 (s,
2H, CH2), 7.02 (d, J = 8.2 Hz, 1H, ArH), 7.38 (d, J = 7.8 Hz, 1H, ArH), 7.46 (d, J = 7.8 Hz, 1H,
ArH), 7.49 (d, J = 1.84 Hz, 1H, ArH), 7.52 (d, J = 1.76 Hz, 1H, ArH), 7.72 (t, 1H, ArH), 9.82 (s,
1H, CHO). The following compound was used for the synthesis of TD-8-1 (43).
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2-Bromothyl nitrate (58):

Compound 58 was prepared as described.152 Sulfuric acid (95%, 4.8 mL) was added in a drop
wise manner to nitric acid (75%, 2.2 mL) at 0 °C (ice-bath). The mixture was allowed to stir for
10 min and 2-bromoethanol (2.5 g, 20 mmol) (57) in CH2Cl2 (20 mL) was added in a drop wise
manner and mixture was allowed to stir for 3 h at room temperature. The mixture was poured
into H2O (100 mL), extracted with CH2Cl2 (3 x 50 mL), dried over MgSO4, and evaporated
under reduced pressure to give crude 58. 1H-NMR (CDCl3): δ 3.55 (t, 2H, CH2), 4.75 (t, 2H,
CH2). The crude was used immediately without purification for the synthesis of compound DD-1
(44).
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2. Blood collection and purification of hemoglobin
Human blood samples for OEC studies were obtained from healthy volunteers at Virginia
Commonwealth University. Hemoglobin for OEC and crystallographic studies was purified from
RBCs left over from red cell exchange from the Medical College of Virginia Hospital. The use
of the biological samples has been reviewed and approved by the IRB, in accordance of
institutional regulations.
Purification of Hb for OEC studies and crystallization was performed according to the
literature procedure.153,154 Hemoglobin was prepared from centrifuging human blood at 2500
rpms for 20 min at 4 °C. The supernatant solution, debris and plasma were discarded from the
centrifuge bottles, leaving behind RBCs. The RBCs were washed thrice with an excess volume
of 0.9% NaCl, and once with 1.0% NaCl, each time centrifuging and discarding the supernatant
solution. The RBCs were pooled together into a chilled flask and hemolyzed to free Hb by
adding 1-2 volume excess of 50 mM Tris buffer, pH 8.6 (containing EDTA). The mixture was
allowed to stand in ice for 30 min with occasional stirring. The Hb solution was centrifuged at
10,000 rpm for 2 h at 4 °C. The supernatant Hb solution was pooled into a chilled flask and NaCl
(40-60 mg/mL Hb solution) was slowly added with stirring. Hemoglobin solution was
centrifuged at 10,000 rpm for 2 h at 4 °C to remove any cell stroma remnants. The clear
supernatant Hb solution was pooled into a chilled flask and the “syrupy” pellet was discarded.
Hemoglobin solution was dialyzed against 50 mM Tris buffer, pH 8.6 (containing EDTA) at
4 °C to remove NaCl and/or other low molecular weight impurities. Strips of standard cellulose
dialysis tubing that had been washed 3-4 times and boiled for 10 min in deionized water were
used for dialysis. The dialyzed Hb was further purified by ion-exchange chromatography using
DEAE sephacel to exclude 2,3-DPG. The resin was equilibrated with 50 mM Tris buffer, pH 8.6,
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and the Hb solution was run through the column with 50 mM Tris buffer, pH 8.6 (containing
EDTA). The pooled fractions were concentrated with an Amicon stirred cell (Amicon, Model
402), to a final HbA concentration of about 80-120 mg/mL. Concentrated HbA was stored at
-80 °C.

3.

Oxygen equilibrium curve studies

Compounds that bind to Hb and increase its O2 affinity are potential anti-sickling agents, while
those that decrease the protein affinity for O2 are potential agents to treat ischemic- and hypoxicrelated diseases. The OEC study was conducted therefore to determine whether these compounds
have any effect on Hb affinity for O2 following reported procedure.103 Purified Hb or whole
blood from normal subjects was used for this study. The OEC studies were conducted on whole
blood samples with hematocrit values ranging from 29-36%, and cell-free purified Hb of
10-12 g/dL in the absence or presence of effectors solubilized in DMSO at 2 mM or in some
cases with varying compound concentration. The blood samples were incubated in IL 237
tonometer (Instrumentation Laboratories, Inc., Lexington, MA) for about 5-7 min at 37 ºC
against gas mixture containing O2 concentrations of 0.804%, 2.935% and 5.528% or 0.804%,
2.935% and 8.785% and allowed to equilibrate at O2 tensions of 6, 20, 40 mmHg or 6, 20, 60
mmHg. After equilibration, the sample was removed via syringe and aspirated into a ABL 700
series table top automated blood gas analyzer (Radiometer America, Inc., Westlake, OH) to
determine total hemoglobin (tHb), hematocrit (Hct), pH, pCO2, partial pressure of oxygen (pO2),
and the Hb oxygen saturation values (sO2). Similar procedure was followed for concentration
and time dependent studies. The measured values of pO2 and sO2 at each oxygen saturation level
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were then subjected to a non-linear regression analysis using the program Scientist (Micromath,
Salt Lake City, UT) with the following equation:
pO!
! mmHg
sO! % = 100  × !
P!" (mmHg) +    pO!
! (mmHg)
This equation was used to calculate P50 and Hill coefficient (N) values. Corresponding control
experiments without the test compound (P50control) but containing DMSO were also performed.

A. Oxygen equilibrium studies for left – shifting compounds
For compounds proposed to shift the OEC to the left, blood samples with hematocrit 34-36%,
were incubated against gas mixture containing O2 concentrations of 0.804%, 2.935% and 5.528%
and allowed to equilibrate at O2 tensions of 6, 20, 40 mmHg and then used to obtain the partial
pressure of oxygen (pO2), and the Hb O2 saturation values (sO2).

B. Oxygen equilibrium studies for right – shifting compounds
For compounds proposed to shift the OEC to the right, blood samples with hematocrit 29-32%,
were incubated against gas mixture containing O2 concentrations of 0.804%, 2.935% and 8.785%
and allowed to equilibrate at O2 tensions of 6, 20, 60 mmHg and then used to obtain the partial
pressure of oxygen (pO2), and the Hb oxygen saturation values (sO2).

4.

Griess assay (Nitric oxide detection assay)

The key to the effectiveness of the proposed nitrate ester compounds is their ability to release
NO and give back the parent compound to be able to interact with the vasculature and the Hb
molecule, respectively, to exert their beneficial effects. This study was therefore conducted to
determine the extent of NO release by these compounds following a literature procedure.134
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Solution of the test compound (1 mL of a 2 mM solution in 0.1 M phosphate buffer (pH 7.4))
was mixed thoroughly with a freshly prepared solution of L-cysteine (1 mL of a 36 mM solution
in 0.1 M phosphate buffer, pH 7.4), and incubated at 37 °C, for 1 and 16 h under anaerobic
conditions. After exposure to air for 10 min at 25 °C, an aliquot of the Griess reagent (1 mL)
[freshly prepared by mixing equal volumes of 1.0% sulfanilamide (prepared and stored in
aqueous 5% phosphoric acid) and 0.1% N-naphthylethylenediamine dihydrochloride in water]
was added to equal volume (1 mL) of each incubation solution after mixing. After 10 min,
absorbance was measured at 540 nm using a Hewlett Packard (Agilent) 8453 UV-visible
Spectroscopy. NaNO2 solutions of 1-100 µM concentrations were used to prepare a standard
nitrite curve of absorbance (nm) versus concentration (µM). The NO released (quantitated as
NO!
! release in µM) was calculated from the standard nitrite curve by extrapolation of the
absorbance.

5.

X-ray crystallography

A. Crystallization and structure determination:
Crystallization experiments have been conducted with deoxy-Hb in complex with several
compounds, including TD-1, TD-7 and DD-1, using reported literature procedures.118,154 The
experiment involved 40-60 mg/mL of Hb and about 4-25 molar excess of the AEH. To obtain the
deoxy-Hb crystals, Hb solution was evacuated for at least 1 h to make deoxy-Hb solution. For
non-aldehyde compounds, a few pellets of sodium dithionite (a reducing agent) were added to
facilitate the deoxygenation process. The compound solubilized in DMSO or water was then
added to the Hb and incubated for 30 min to 1 h. For compounds that are aldehydes, sodium
cyanoborohydride (NaCNBH4) in 4-25 molar excess of Hb was added to reduce the reversible
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Schiff base adduct formed between the amino group of Hb and the aldehyde to the corresponding
irreversible alkylamine covalent bond. Subsequent crystallization of the compound-deoxy-Hb
complex solutions in 10 mL test tubes was undertaken using high-salt precipitant of 3.2-3.6 M
sulfate/ phosphate precipitant pH 6.5 or low-salt precipitant of 0.2 M sodium acetate trihydrate,
0.1 M sodium cacodylate trihydrate pH 6.5 and 30% w/v PEG 8000. Ferrous citrate (50 µL),
generated in situ by the reaction of ferrous sulphate and sodium citrate in water, was added to
each of the crystallization tubes, which functioned as antimicrobial. Water was added to any tube
that showed precipitation. The tubes were purged with nitrogen, tightly stoppered and stored in
glass jars. Crystals suitable for mounting grew in 3-5 days. The entire crystallization experiment
was performed in a glovebox under nitrogen atmosphere as described to prevent oxygenation of
the deoxy-Hb to oxy-Hb and met-Hb forms.154,155
Crystals obtained from the deoxy-Hb in complex with TD-1, TD-7 or DD-1 were used for
X-ray diffraction data collection at 100K with a R-axis IV++ image-plate detector using CuKα
x-rays (λ = 1.54 Å) from Rigaku Micro-MaxTM -007 x-ray source equipped with varimax
confocal optics (Rigaku, The Woodlands, TX) operating at 40 kv and 20 mA. Prior to use, the
crystals were washed in a cryo-protectant solution containing mother liquor and glycerol and
then flash frozen. The collected data sets were processed with MSC d*TREK software program
and the CCP4 suite of programs.156
The structures were determined by a molecular replacement method with the program
Phenix140 and refined with the program CNS.141 Model building and corrections were carried out
using graphics programs TOM157 and Coot.158
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(i) Structure determination of deoxy-Hb in complex with TD-1
Crystallization of the deoxy-Hb in complex with TD-1 was undertaken using the high-salt
condition. Deoxy-Hb or T-state dark purple, rectangular crystals grew to a size of about 0.2 x 0.3
x 0.4 mm in 3-5 days. The structure was solved by molecular replacement using the native
human deoxy-Hb structure (PDB ID: 2HHB)26 as the search model, and refined to an
Rfactor/Rfree of 16.71%/ 19.22%.

(ii) Structure determination of deoxy-Hb in complex with TD-7
Crystallization of deoxy-Hb in complex with TD-7 was undertaken using the low-salt condition.
Deoxy-Hb or T-state dark purple, rectangular crystals grew to a size of about 0.2 x 0.3 x 0.4 mm
in 3-5 days. After a month, a different crystal form, reddish in color and trigonal bipyrimidal
began to form in the same crystallization tube as the T-state crystals. These crystals are R-state
crystals, which did not grow to a suitable size even after 10 months. The structure was solved by
molecular replacement using the native human deoxy-Hb structure (PDB ID: 2HHB)26 as the
search model, and refined to an Rfactor/Rfree of 24.02%/29.59%.

(iii) Structure determination of deoxy-Hb in complex with DD-1
Crystallization of deoxy-Hb in complex with DD-1 was undertaken using the low-salt condition.
Deoxy-Hb or T-state dark purple, rectangular crystals grew to a size of about 0.2 x 0.3 x 0.4 mm
in 3-5 days. The structure was solved by molecular replacement using the deoxy-Hb structure in
complex with RSR-13 (PDB ID: 1G9V)28 as the search model, and refined to an Rfactor/Rfree of
22.38%/26.38%.

120	
  
	
  

	
  
	
  

BIBLIOGRAPHY

1.

Wireko, F. C.; Kellogg, G. E.; Abraham, D. J. Allosteric modifiers of hemoglobin 2.

Crystallographically determined binding sites and hydrophobic binding/interaction analysis of
novel hemoglobin oxygen effectors. J. Med. Chem. 1991, 34, 758-67.
2.

Hsia, C. C. W. Respiratory function of hemoglobin. N. Engl. J. Med. 1998, 338, 239-248.

3.

Safo, M. K.; Ahmed, M. H.; Ghatge, M. S.; Boyiri, T. Hemoglobin–ligand binding:

Understanding Hb function and allostery on atomic level. BBA - Proteins Proteom. 2011, 1814,
797-809.
4.

Benesch, R.; Benesch, R. E. The effect of organic phosphates from the human

erythrocyte on the allosteric properties of hemoglobin. Biochem. Biophys. Res. Commun. 1967,
26, 162-167.
5.

Arnone, A. X-ray diffraction study of binding of 2,3-diphosphoglycerate to human

deoxyhaemoglobin. Nature 1972, 237, 146-149.
6.

Richard,

V.;

Dodson,

G.

G.;

Mauguen,

Y.

Human

deoxyhaemoglobin-2,3-

diphosphoglycerate complex low-salt structure at 2.5 Å resolution. J. Mol. Biol. 1993, 233, 270274.

121	
  
	
  

	
  
	
  

7.

Bettati, S.; Mozzarelli, A.; Perutz, M. F. Allosteric mechanism of haemoglobin: Rupture

of salt-bridges raises the oxygen affinity of the T-structure. J. Mol. Biol. 1998, 281, 581-585.
8.

Perutz, M. F.; Wilkinson, A. J.; Paoli, M.; Dodson, G. G. The stereochemical mechanism

of the cooperative effects in hemoglobin revisited. Annu. Rev. Biophys. Biomol. Struct. 1998, 27,
1-34.
9.

Mozzarelli, A.; Rivetti, C.; Rossi, G. L.; Henry, E. R.; Eaton, W. A. Crystals of

haemoglobin with the T quaternary structure bind oxygen noncooperatively with no bohr effect.
Nature 1991, 351, 416-419.
10.

Perutz, M. F. Structure and mechanism of haemoglobin. Br. Med. Bull. 1976, 32, 195-

208.
11.

Stea, B.; Shaw, E.; Pinter, T.; Hackman, J.; Craig, M.; May, J.; Steffen, R. P.; Suh, J. H.

Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br. J.
Cancer 2006, 94, 1777-1784.
12.

Parkhurst, L. J. Hemoglobin and myoglobin ligand kinetics. Annu. Rev. Phys. Chem.

1979, 30, 503-546.
13.

Bhagavan, N. V. Medical biochemistry, 4th ed.; Academic Press: San Diego, 2002.

14.

Najjar, S. B.; Bottomley, P. A.; Schulman, S. M.; Waldron, M. M.; Steffen, R. P.;

Gerstenblith, G.; Weiss, R. G. Effects of a pharmacologically-induced shift of hemoglobinoxygen dissociation on myocardial energetics during ischemia in patients with coronary artery
disease. J. Cardiov. Magn. Reson. 2005, 7, 657-666.
15.

Kilgore, K. S.; Shwartz, C. F.; Gallagher, M. A.; Steffen, R. P.; Mosca, R. S.; Bolling, S.

F. RSR13, a synthetic allosteric modifier of hemoglobin, improves myocardial recovery
following hypothermic cardiopulmonary bypass. Circulation 1999, 100, II-351-II-356.

122	
  
	
  

	
  
	
  

16.

Berlin, G.; Challoner, K. E.; Woodson, R. D. Low-O2 affinity erythrocytes improve

performance of ischemic myocardium. J. Appl. Physiol. 2002, 92, 1267-1276.
17.

Abraham, D. J.; Mehanna, A. S.; Wireko, F. C.; Whitney, J.; Thomas, R. P.; Orringer, E.

P. Vanillin, a potential agent for the treatment of sickle cell anemia. Blood 1991, 77, 1334-1341.
18.

Abdulmalik, O.; Safo, M. K.; Chen, Q.; Yang, J.; Brugnara, C.; Ohene-Frempong, K.;

Abraham, D. J.; Asakura, T. 5-Hydroxymethyl-2-furfural modifies intracellular sickle
haemoglobin and inhibits sickling of red blood cells. Br. J. Haematol. 2005, 128, 552-561.
19.

Ingram, V. M. Gene mutations in human haemoglobin: The chemical difference between

normal and sickle cell haemoglobin. Nature 1957, 180, 326-8.
20.

Dykes, G. W.; Crepeau, R. H.; Edelstein, S. J. Three-dimensional reconstruction of the

14-filament fibers of hemoglobins. J. Mol. Biol. 1979, 130, 451-472.
21.

Galkin, O.; Pan, W.; Filobelo, L.; Hirsch, R. E.; Nagel, R. L.; Vekilov, P. G. Two-step

mechanism of homogeneous nucleation of sickle cell hemoglobin polymers. Biophys. J. 2007,
93, 902-913.
22.

Seakins, M.; Gibbs, W. N.; Milner, P. F.; Bertles, J. F. Erythrocyte Hb-S concentration.

An important factor in the low oxygen affinity of blood in sickle cell anemia. J. Clin. Invest.
1973, 52, 422-432.
23.

Muirhead, H.; Perutz, M. F. Structure of haemoglobin. A three-dimensional fourier

synthesis of reduced human haemoglobin at 5.5 Å resolution. Nature 1963, 199, 633-638.
24.

Richards, F. M.; Phillips, D. C. Atlas of molecular structures in biology, Oxford

University Press: Oxford, 1973.

123	
  
	
  

	
  
	
  

25.

Perutz, M. F.; Muirhead, H.; Cox, J. M.; Goaman, L. C. Three-dimensional fourier

synthesis of horse oxyhaemoglobin at 2.8 Å resolution: The atomic model. Nature 1968, 219,
131-139.
26.

Fermi, G.; Perutz, M. F.; Shaanan, B.; Fourme, R. The crystal structure of human

deoxyhaemoglobin at 1.74 Å resolution. J. Mol. Biol. 1984, 175, 159-174.
27.

Bellelli, A.; Brunori, M.; Miele, A. E.; Panetta, G.; Vallone, B. The allosteric properties

of hemoglobin: Insights from natural and site directed mutants. Curr. Protein Pept. Sci. 2006, 7,
17-45.
28.

Safo, M. K.; Moure, C. M.; Burnett, J. C.; Joshi, G. S.; Abraham, D. J. High-resolution

crystal structure of deoxy hemoglobin complexed with a potent allosteric effector. Protein Sci.
2001, 10, 951-957.
29.

Monod, J.; Wyman, J.; Changeux, J. P. On the nature of allosteric transitions: A plausible

model. J. Mol. Biol. 1965, 12, 88-118.
30.

Gomez-Cambronero, J. The oxygen dissociation curve of hemoglobin: Bridging the gap

between biochemistry and physiology. J. Chem. Educ. 2001, 78, 757.
31.

Mozzarelli, A.; Rivetti, C.; Rossi, G. L.; Eaton, W. A.; Henry, E. R. Allosteric effectors

do not alter the oxygen affinity of hemoglobin crystals. Protein Sci. 1997, 6, 484-489.
32.

Yonetani, T.; Park, S.; Tsuneshige, A.; Imai, K.; Kanaori, K. Global allostery model of

hemoglobin: Modulation of O2 affinity, cooperativity, and bohr effect by heterotropic allosteric
effectors. J. Biol. Chem. 2002, 277, 34508-34520.
33.

Riggs, A. F. The bohr effect. Annual Review of Physiology 1988, 50, 181-204.

124	
  
	
  

	
  
	
  

34.

Thein, S. L.; Menzel, S.; Lathrop, M.; Garner, C. Control of fetal hemoglobin: New

insights emerging from genomics and clinical implications. Hum. Mol. Gen. 2009, 18, R216R223.
35.

Akinsheye, I.; Alsultan, A.; Solovieff, N.; Ngo, D.; Baldwin, C. T.; Sebastiani, P.; Chui,

D. H. K.; Steinberg, M. H. Fetal hemoglobin in sickle cell anemia. Blood 2011, 118, 19-27.
36.

Berg, J. M.; Tymoczko, J. L.; Stryer, L. Biochemistry, 5th ed.; W.H. Freeman: New

York, 2002.
37.

Mozzarelli, A.; Bettati, S. Chemistry and biochemistry of oxygen therapeutics: From

transfusion to artificial blood, Wiley: Hoboken, NJ, USA, 2011.
38.

Hess, D. Respiratory care : Principles and practice, 2nd ed.; Jones & Bartlett Learning:

Sudbury, MA, 2012.
39.

Franklin, I. M.; Huehns, E. R.; Rosemeyer, M. A. Increasing haemoglobin oxygen

affinity to prevent sickling: Abnormal haemoglobin variants as models. Br. J. Haematol. 1986,
64, 319-329.
40.

Abdulmalik, O.; Safo, M. K.; Chen, Q.; Yang, J.; Brugnara, C.; Ohene-Frempong, K.;

Abraham, D. J.; Asakura, T. 5-Hydroxymethyl-2-furfural modifies intracellular sickle
haemoglobin and inhibits sickling of red blood cells. Br. J. Haematol. 2005, 128, 552-561.
41.

Coleman, E.; Inusa, B. Sickle cell anemia: Targeting the role of fetal hemoglobin in

therapy. Clin. Pediatr. (Phila) 2007, 46, 386-391.
42.

Clerbaux, T.; Detry, B.; Reynaert, M.; Frans, A. Right shift of the oxyhemoglobin

dissociation curve in acute respiratory distress syndrome. Pathol. Biol. (Paris) 1997, 45, 269273.

125	
  
	
  

	
  
	
  

43.

Forget, B. G.; Bunn, H. F. Classification of the disorders of hemoglobin. Cold Spring

Harb. Perspect. Med. 2013, 3, a011684.
44.

Rees, D. C.; Williams, T. N.; Gladwin, M. T. Sickle-cell disease. The Lancet 2010, 376,

2018-2031.
45.

Billo, M. A.; Johnson, E. S.; Doumbia, S. O.; Poudiougou, B.; Sagara, I.; Diawara, S. I.;

Diakité, M.; Diallo, M.; Doumbo, O. K.; Tounkara, A.; Rice, J.; James, M. A.; Krogstad, D. J.
Sickle cell trait protects against plasmodium falciparum infection. Am. J. Epidemiol. 2012, 176,
S175-S185.
46.

Pauling, L.; Itano, H. A.; Singer, S. J.; Wells, I. C. Sickle cell anemia, a molecular

disease. Science 1949, 110, 543-548.
47.

Cotton, F.; Gulbis, B. Separation of hemoglobin variants by capillary electrophoresis.

Methods Mol. Biol. 2013, 919, 121-130.
48.

Maciaszek, J. L.; Lykotrafitis, G. Sickle cell trait human erythrocytes are significantly

stiffer than normal. J. Biomech. 2011, 44, 657-661.
49.

Aliyu, Z. Y.; Tumblin, A. R.; Kato, G. J. Current therapy of sickle cell disease.

Haematologica 2006, 91, 7-10.
50.

Morris, C. R.; Kato, G. J.; Poljakovic, M.; Wang, X.; Blackwelder, W. C.; Sachdev, V.;

Hazen, S. L.; Vichinsky, E. P.; Morris, S. M., Jr.; Gladwin, M. T. Dysregulated arginine
metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.
JAMA 2005, 294, 81-90.
51.

Walford, G.; Loscalzo, J. Nitric oxide in vascular biology. J. Thromb. Haemost. 2003, 1,

2112-2118.

126	
  
	
  

	
  
	
  

52.

Maley, J. H.; Lasker, G. F.; Kadowitz, P. J. Nitric oxide and disorders of the erythrocyte:

Emerging roles and therapeutic targets. Cardiovasc. Hematol. Disord. Drug Targets 2010, 10,
284-291.
53.

Hassell, K. L. Population estimates of sickle cell disease in the USA. Am. J. Prev. Med.

2010, 38, S512-S521.
54.

Russell, P. J. Igenetics: A molecular approach, 3rd ed.; Benjamin Cummings: San

Francisco, 2010.
55.

Wishner, B. C.; Ward, K. B.; Lattman, E. E.; Love, W. E. Crystal structure of sickle-cell

deoxyhemoglobin at 5 Å resolution. J. Mol. Biol. 1975, 98, 179-194.
56.

Noguchi, C. T.; Schechter, A. N. Sickle hemoglobin polymerization in solution and in

cells. Annu. Rev. Biophys. Biophys. Chem. 1985, 14, 239-263.
57.

Sunshine, H. R.; Hofrichter, J.; Eaton, W. A. Requirement for therapeutic inhibition of

sickle haemoglobin gelation. Nature 1978, 275, 238-240.
58.

Bunn, H. F.; Forget, B. G. Hemoglobin: Molecular, genetic and clinical aspects. Ann.

Intern. Med. 1986, 105, 820-820.
59.

Platt, O. S. Hydroxyurea for the treatment of sickle cell anemia. N. Engl. J. Med. 2008,

358, 1362-1369.
60.

Charache, S.; Dover, G. J.; Moore, R. D.; Eckert, S.; Ballas, S. K.; Koshy, M.; Milner, P.

F.; Orringer, E. P.; Phillips, G., Jr.; Platt, O. S. Hydroxyurea: Effects on hemoglobin F
production in patients with sickle cell anemia. Blood 1992, 79, 2555-2565.
61.

Ameh, S. J.; Tarfa, F. D.; Ebeshi, B. U. Traditional herbal management of sickle cell

anemia: Lessons from nigeria. Anemia 2012, 2012, 607436.

127	
  
	
  

	
  
	
  

62.

Akojie, F. O.; Fung, L. W. Antisickling activity of hydroxybenzoic acids in cajanus

cajan. Planta. Med. 1992, 58, 317-320.
63.

Iyamu, E. W.; Turner, E. A.; Asakura, T. In vitro effects of niprisan (Nix-0699): A

naturally occurring, potent antisickling agent. Br. J. Haematol. 2002, 118, 337-343.
64.

Watson, J. The significance of the paucity of sickle cells in newborn negro infants. Am. J.

Med. Sci. 1948, 215, 419-423.
65.

Perrine, R. P.; Pembrey, M. E.; John, P.; Perrine, S.; Shoup, F. Natural history of sickle

cell anemia in saudi arabsa study of 270 subjects. Ann. Intern. Med. 1978, 88, 1-6.
66.

Atweh, G.; Fathallah, H. Pharmacologic induction of fetal hemoglobin production.

Hematol. Oncol. Clin. North Am. 2010, 24, 1131-1144.
67.

Kar, B. C.; Kulozik, A. E.; Sirr, S.; Satapathy, R. K.; Kulozik, M.; Serjeant, B. E.;

Serjeant, G. R. Sickle cell disease in Orissa state, India. The Lancet 1986, 328, 1198-1201.
68.

Ley, T. J.; DeSimone, J.; Noguchi, C. T.; Turner, P. H.; Schechter, A. N.; Heller, P.;

Nienhuis, A. W. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of
dense cells in patients with sickle cell anemia. Blood 1983, 62, 370-380.
69.

Makis, A. C.; Hatzimichael, E. C.; Stebbing, J. The genomics of new drugs in sickle cell

disease. Pharmacogenomics 2006, 7, 909-917.
70.

DeSimone, J.; Koshy, M.; Dorn, L.; Lavelle, D.; Bressler, L.; Molokie, R.; Talischy, N.

Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of
sickle cell anemia. Blood 2002, 99, 3905-3908.
71.

Nagel, R. L.; Vichinsky, E.; Shah, M.; Johnson, R.; Spadacino, E.; Fabry, M. E.;

Mangahas, L.; Abel, R.; Stamatoyannopoulos, G. Reticulocyte response in sickle cell anemia
treated with recombinant human erythropoietin: A double-blind study. Blood 1993, 81, 9-14.

128	
  
	
  

	
  
	
  

72.

Atweh, G. F.; Sutton, M.; Nassif, I.; Boosalis, V.; Dover, G. J.; Wallenstein, S.; Wright,

E.; McMahon, L.; Stamatoyannopoulos, G.; Faller, D. V.; Perrine, S. P. Sustained induction of
fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999, 93, 1790-1797.
73.

Walters, M. C. Stem cell therapy for sickle cell disease: Transplantation and gene

therapy. Hematology Am. Soc. Hematol. Educ. Program 2005, 2005, 66-73.
74.

Smiers, F. J.; Krishnamurti, L.; Lucarelli, G. Hematopoietic stem cell transplantation for

hemoglobinopathies: Current practice and emerging trends. Pediatr. Clin. North Am. 2010, 57,
181-205.
75.

Bolanos-Meade, J.; Brodsky, R. A. Blood and marrow transplantation for sickle cell

disease: Overcoming barriers to success. Curr. Opin. Oncol. 2009, 21, 158-161.
76.

Thompson, L. M.; Ceja, M. E.; Yang, S. P. Stem cell transplantation for treatment of

sickle cell disease: Bone marrow versus cord blood transplants. Am. J. Health Syst. Pharm. 2012,
69, 1295-1302.
77.

Hsieh, M. M.; Kang, E. M.; Fitzhugh, C. D.; Link, M. B.; Bolan, C. D.; Kurlander, R.;

Childs, R. W.; Rodgers, G. P.; Powell, J. D.; Tisdale, J. F. Allogeneic hematopoietic stem-cell
transplantation for sickle cell disease. N. Engl. J. Med. 2009, 361, 2309-2317.
78.

Abu-Salah, K. M.; Gambo, A. H. A. An analysis of the mechanism by which cetiedil

inhibits sickling. Life Sci. 2002, 70, 1003-1011.
79.

Steinberg, M. H. Management of sickle cell disease. N. Engl. J. Med. 1999, 340, 1021-

1030.
80.

Ballas, S. K. Sickle cell anaemia: Progress in pathogenesis and treatment. Drugs 2002,

62, 1143-1172.

129	
  
	
  

	
  
	
  

81.

Johnston, M. N.; Ellory, J. C.; Stuart, J. Bepridil protects sickle cells against the adverse

rheological effects of cyclical deoxygenation. Br. J. Haematol. 1989, 73, 522-526.
82.

Johnson, R. M.; Acquaye, C.; Feo, C.; Sarnaik, S. Bepridil as an antisickling agent:

Membrane internalization and cell rigidity. Am. J. Hematol. 1994, 46, 310-318.
83.

Asakura, T.; Shibutani, Y.; Reilly, M. P.; DeMeio, R. H. Antisickling effect of tellurite:

A potent membrane-acting agent in vitro. Blood 1984, 64, 305-307.
84.

De Franceschi, L.; Corrocher, R. Established and experimental treatments for sickle cell

disease. Haematologica 2004, 89, 348-356.
85.

Amrolia, P. J.; Almeida, A.; Halsey, C.; Roberts, I. A. G.; Davies, S. C. Therapeutic

challenges in childhood sickle cell disease part 1: Current and future treatment options. Br. J.
Haematol. 2003, 120, 725-736.
86.

Wishner, B. C.; Ward, K. B.; Lattman, E. E.; Love, W. E. Crystal structure of sickle-cell

deoxyhemoglobin at 5 Å resolution. J. Mol. Biol. 1975, 98, 179-194.
87.

Mehanna, A. S. Sickle cell anemia and antisickling agents then and now. Curr. Med.

Chem. 2001, 8, 79-88.
88.

Pariser, S.; Katz, A. Treatment of sickle cell trait hematuria with oral urea. J. Urol. 1994,

151, 401-403.
89.

Elbaum, D.; Roth, E. F., Jr.; Neumann, G.; Jaffe, E. R.; Bookchin, R. M.; Nagel, R. L.

Molecular and cellular effects of antisickling concentrations of alkylureas. Blood 1976, 48, 273282.
90.

Kumpati, J. Liposome-loaded phenylalanine or tryptophan as sickling inhibitor: A

possible therapy for sickle cell disease. Biochem. Med. Metab. Biol. 1987, 38, 170-181.

130	
  
	
  

	
  
	
  

91.

Klotz, I. M.; Haney, D. N.; King, L. C. Rational approaches to chemotherapy:

Antisickling agents. Science 1981, 213, 724-731.
92.

Poillon, W. N. Noncovalent inhibitors of sickle hemoglobin gelation: Effects of aryl-

substituted alanines. Biochemistry 1982, 21, 1400-1406.
93.

Noguchi, C. T.; Schechter, A. N. Inhibition of sickle hemoglobin gelation by amino acids

and related compounds. Biochemistry 1978, 17, 5455-5459.
94.

Abraham, D. J.; Kennedy, P. E.; Mehanna, A. S.; Patwa, D. C.; Williams, F. L. Design,

synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of
benzyloxy and phenoxy acids. J. Med. Chem. 1984, 27, 967-978.
95.

Abraham, D. J.; Gazze, D. M.; Kennedy, P. E.; Mokotoff, M. Design, synthesis, and

testing of potential antisickling agents 5. Disubstituted benzoic acids designed for the donor site
and proline salicylates designed for the acceptor site. J. Med. Chem. 1984, 27, 1549-1559.
96.

Fall, A. B. K.; Toppet, M.; Ferster, A.; Fondu, P.; Vanhaelen-Fastré, R.; Vanhaelen, M.

In vitro antisickling activity of cromolyn sodium. Br. J. Haematol. 1998, 103, 957-959.
97.

Gillette, P. N.; Peterson, C. M.; Lu, Y. S.; Cerami, A. Sodium cyanate as a potential

treatment for sickle-cell disease. N. Engl. J. Medicine 1974, 290, 654-660.
98.

Roth Jr, E. F.; Nagel, R. L.; Bookchin, R. M.; Grayzel, A. I. Nitrogen mustard: An “in

vitro” inhibitor of erythrocyte sickling. Biochem. Biophys. Res. Commun. 1972, 48, 612-618.
99.

Kennedy, P. E.; Williams, F. L.; Abraham, D. J. Design, synthesis, and testing of

potential antisickling agents. 3. Ethacrynic acid. J. Med. Chem. 1984, 27, 103-105.
100.

Klotz, I. M.; Tam, J. W. Acetylation of sickle cell hemoglobin by aspirin. Proc. Natl.

Acad. Sci. USA 1973, 70, 1313-1315.

131	
  
	
  

	
  
	
  

101.

Xu, A. S. L.; Labotka, R. J.; London, R. E. Acetylation of human hemoglobin by methyl

acetylphosphate: Evidence of broad regio-selectivity revealed by NMR studies. J. Biol. Chem.
1999, 274, 26629-26632.
102.

Hassan, W.; Beuzard, Y.; Rosa, J. Inhibition of erythrocyte sickling by cystamine, a thiol

reagent. Proc. Natl. Acad. Sci. USA 1976, 73, 3288-3292.
103.

Nnamani, I. N.; Joshi, G. S.; Danso-Danquah, R.; Abdulmalik, O.; Asakura, T.;

Abraham, D. J.; Safo, M. K. Pyridyl derivatives of benzaldehyde as potential antisickling agents.
Chem. Biodivers. 2008, 5, 1762-1769.
104.

Kark, J. A.; Tarassoff, P. G.; Bongiovanni, R. Pyridoxal phosphate as an antisickling

agent in vitro. J. Clin. Invest. 1983, 71, 1224-1229.
105.

Wireko, F. C.; Abraham, D. J. X-ray diffraction study of the binding of the antisickling

agent 12C79 to human hemoglobin. Proc. Natl. Acad. Sci. USA 1991, 88, 2209-2211.
106.

Abdulmalik, O.; Ghatge, M. S.; Musayev, F. N.; Parikh, A.; Chen, Q.; Yang, J.;

Nnamani, I.; Danso-Danquah, R.; Eseonu, D. N.; Asakura, T.; Abraham, D. J.; Venitz, J.; Safo,
M. K. Crystallographic analysis of human hemoglobin elucidates the structural basis of the
potent and dual antisickling activity of pyridyl derivatives of vanillin. Acta Crystallogr. D: Biol.
Crystallogr. 2011, 67, 920-928.
107.

Zaugg, R. H.; Walder, J. A.; Klotz, I. M. Schiff base adducts of hemoglobin.

Modifications that inhibit erythrocyte sickling. J. Biol. Chem. 1977, 252, 8542-8548.
108.

Gladwin, M. T.; Schechter, A. N. Nitric oxide therapy in sickle cell disease. Sem.

Hematol. 2001, 38, 333-342.
109.

Kahn, M. J.; Maley, J. H.; Lasker, G. F.; Kadowitz, P. J. Updated role of nitric oxide in

disorders of erythrocyte function. Cardiovasc. Hematol. Disord. Drug Targets 2013, 13, 83-87.

132	
  
	
  

	
  
	
  

110.

Abraham, D. J.; Perutz, M. F.; Phillips, S. E. Physiological and X-ray studies of potential

antisickling agents. Proc. Natl. Acad. Sci. USA 1983, 80, 324-328.
111.

Perutz, M. F.; Poyart, C. Bezafibrate lowers oxygen affinity of haemoglobin. The Lancet

1983, 322, 881-882.
112.

Randad, R. S.; Mahran, M. A.; Mehanna, A. S.; Abraham, D. J. Allosteric modifiers of

hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel
hemoglobin oxygen affinity decreasing agents. J. Med. Chem. 1991, 34, 752-7.
113.

Watson, J. C.; Doppenberg, E. M. R.; Bullock, M. R.; Zauner, A.; Rice, M. R.; Abraham,

D.; Young, H. F. Effects of the allosteric modification of hemoglobin on brain oxygen and
infarct size in a feline model of stroke. Stroke 1997, 28, 1624-1630.
114.

Watanabe, T.; Takeda, T.; Omiya, S.; Hikoso, S.; Yamaguchi, O.; Nakano, Y.; Higuchi,

Y.; Nakai, A.; Abe, Y.; Aki-Jin, Y.; Taniike, M.; Mizote, I.; Matsumura, Y.; Shimizu, T.;
Nishida, K.; Imai, K.; Hori, M.; Shirasawa, T.; Otsu, K. Reduction in hemoglobin–oxygen
affinity results in the improvement of exercise capacity in mice with chronic heart failure. J. Am.
Coll. Cardiol. 2008, 52, 779-786.
115.

Youssef, A. M.; Safo, M. K.; Danso-Danquah, R.; Joshi, G. S.; Kister, J.; Marden, M. C.;

Abraham, D. J. 281. J. Med. Chem. 2002, 45, 1184-1195.
116.
F.;

Abraham, D. J.; Wireko, F. C.; Randad, R. S.; Poyart, C.; Kister, J.; Bohn, B.; Liard, J.
Kunert,

M.

P.

Allosteric

modifiers

of

hemoglobin:

2-[4-[[(3,5-disubstituted

anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen
affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry
1992, 31, 9141-9149.

133	
  
	
  

	
  
	
  

117.

Vekilov, P. G. Sickle-cell haemoglobin polymerization: Is it the primary pathogenic

event of sickle-cell anaemia? Br. J. Haematol 2007, 139, 173-184.
118.

Safo, M. K.; Abdulmalik, O.; Danso-Danquah, R.; Burnett, J. C.; Nokuri, S.; Joshi, G. S.;

Musayev, F. N.; Asakura, T.; Abraham, D. J. Structural basis for the potent antisickling effect of
a novel class of five-membered heterocyclic aldehydic compounds. J. Med. Chem. 2004, 47,
4665-4676.
119.

Parikh, A.; Ghatge, M.; Safo, M; Venitz, J. Comparative pharmacodynamic (PD)

profiling of the in-vitro time- and concentration- dependent effects of known, synthetic allosteric
effectors of hemoglobin (AEH). Presented at the 2011 American Association of Pharmaceutical
Scientists (AAPS) Annual Meeting and Exposition, Washington, DC, October 2011.
120.

Sun, K.; Xia, Y. New insights into sickle cell disease: A disease of hypoxia. Curr. Opin.

Hematol. 2013, 20, 215-221.
121.

Ricart-Jané, D.; Llobera, M.; López-Tejero, M. D. Anticoagulants and other preanalytical

factors interfere in plasma nitrate/nitrite quantification by the griess method. Nitric Oxide 2002,
6, 178-185.
122.

Mack, A. K.; Kato, G. J. Sickle cell disease and nitric oxide: A paradigm shift? Int. J.

Biochem. Cell Biol. 2006, 38, 1237-1243.
123.

Girgis, R. E.; Qureshi, M. A.; Abrams, J.; Swerdlow, P. Decreased exhaled nitric oxide in

sickle cell disease: Relationship with chronic lung involvement. Am. J. Hematol. 2003, 72, 177184.
124.

Hunter, C. J.; Dejam, A.; Blood, A. B.; Shields, H.; Kim-Shapiro, D. B.; Machado, R. F.;

Tarekegn, S.; Mulla, N.; Hopper, A. O.; Schechter, A. N.; Power, G. G.; Gladwin, M. T. Inhaled

134	
  
	
  

	
  
	
  

nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat.
Med. 2004, 10, 1122-1127.
125.

Weiner D. L.; Hibberd, P. L.; Betit, P.; Cooper, A. B.; Botelho, C. A.; Brugngra, C.

Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients
with sickle cell disease. JAMA 2003, 289, 1136-1142.
126.

Miller, M. R.; Megson, I. L. Recent developments in nitric oxide donor drugs. Br. J.

Pharmacol. 2007, 151, 305-21.
127.

de Franceschi, L.; Baron, A.; Scarpa, A.; Adrie, C.; Janin, A.; Barbi, S.; Kister, J.;

Rouyer-Fessard, P.; Corrocher, R.; Leboulch, P.; Beuzard, Y. Inhaled nitric oxide protects
transgenic

sad

mice

from

sickle

cell

disease–specific

lung

injury

induced

by

hypoxia/reoxygenation. Blood 2003, 102, 1087-1096.
128.

Berlin, G.; Challoner, K. E.; Woodson, R. D. Low-O2 affinity erythrocytes improve

performance of ischemic myocardium. J. Appl. Physiol. 2002, 92, 1267-1276.
129.

Hou, H.; Khan, N.; Grinberg, O. Y.; Yu, H.; Grinberg, S. A.; Lu, S.; Demidenko, E.;

Steffen, R. P.; Swartz, H. M. The effects of Efaproxyn™ (efaproxiral) on subcutaneous RIF-1
tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in
mice. Radiat. Res. 2007, 168, 218-225.
130.

Kunert, M. P.; Liard, J. F.; Abraham, D. J.; Lombard, J. H. Low-affinity hemoglobin

increases tissue PO2 and decreases arteriolar diameter and flow in the rat cremaster muscle.
Microvasc. Res. 1996, 52, 58-68.
131.

Purves, W. K.; Orians, G. H.; Heller, H. C. Life: The science of biology, 9th ed.; Sinauer

Associates; W.H. Freeman: Sunderland, MA; New York, NY, 1992.

135	
  
	
  

	
  
	
  

132.

Sun, J.; Zhang, X.; Broderick, M.; Fein, H. Measurement of nitric oxide production in

biological systems by using griess reaction assay. Sensors 2003, 3, 276-284.
133.

Tsikas, D. Analysis of nitrite and nitrate in biological fluids by assays based on the griess

reaction: Appraisal of the griess reaction in the L-arginine/nitric oxide area of research. J.
Chromatogr. B 2007, 851, 51-70.
134.

Molecular probes, Inc. Griess reagent kit for nitrite determination (G-7921). Product

information, July 2003; 1-3.
135.

Naimi, E.; Zhou, A.; Khalili, P.; Wiebe, L. I.; Balzarini, J.; De Clercq, E.; Knaus, E. E.

Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "Nitric oxide donor" agents
for evaluation as anticancer and antiviral agents. J. Med. Chem. 2003, 46, 995-1004.
136.

Feelisch, M. The biochemical pathways of nitric oxide formation from nitrovasodilators:

Appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous
NO solutions. J. Cardiovasc. Pharmacol. 1991, 17, S25-S33.
137.

Hibbs, J. B., Jr.; Taintor, R. R.; Vavrin, Z. Macrophage cytotoxicity: Role for L-arginine

deiminase and imino nitrogen oxidation to nitrite. Science 1987, 235, 473-476.
138.

Hibbs, J. B., Jr.; Taintor, R. R.; Vavrin, Z.; Rachlin, E. M. Nitric oxide: A cytotoxic

activated macrophage effector molecule. Biochem. Biophys. Res. Commun. 1988, 157, 87-94.
139.

Pietraforte, D.; Mallozzi, C.; Scorza, G.; Minetti, M. Role of thiols in the targeting of s-

nitroso thiols to red blood cells. Biochemistry 1995, 34, 7177-7185.
140.

Adams, P. D.; Afonine, P. V.; Bunkóczi, G.; Chen, V. B.; Echols, N.; Headd, J. J.; Hung,

L.-W.; Jain, S.; Kapral, G. J.; Grosse Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner,
R. D.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. The

136	
  
	
  

	
  
	
  

phenix software for automated determination of macromolecular structures. Methods 2011, 55,
94-106.
141.

Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve,

R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson,
T.; Warren, G. L. Crystallography & NMR system: A new software suite for macromolecular
structure determination. Acta Crystallogr. Sec. D: Biol. Crystallogr. 1998, 54, 905-921.
142.

Abraham, D. J.; Safo, M. K.; Boyiri, T.; Danso-Danquah, R. E.; Kister, J.; Poyart, C.

How allosteric effectors can bind to the same protein residue and produce opposite shifts in the
allosteric equilibrium. Biochemistry 1995, 34, 15006-15020.
143.

Wahr, J. A.; Gerber, M.; Venitz, J.; Baliga, N. Allosteric modification of oxygen delivery

by hemoglobin. Anesth. Analg. 2001, 92, 615-620.
144.

Boschan, R.; Merrow, R. T.; van Dolah, R. W. The chemistry of nitrate esters. Chem.

Rev. 1955, 55, 485-510.
145.

Breidbach, A.; Catlin, D. H. RSR13, a potential athletic performance enhancement agent:

Detection in urine by gas chromatography/mass spectrometry. Rapid Commun. Mass Spectrom.
2001, 15, 2379-2382.
146.

Springsteel, M. F.; Galietta, L. J. V.; Ma, T.; By, K.; Berger, G. O.; Yang, H.; Dicus, C.

W.; Choung, W.; Quan, C.; Shelat, A. A.; Guy, R. K.; Verkman, A. S.; Kurth, M. J.; Nantz, M.
H. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: Towards
a pharmacophore model for the nucleotide-binding domain. Bioorg. Med. Chem. 2003, 11, 41134120.

137	
  
	
  

	
  
	
  

147.

Gavrila, A.; Andersen, L.; Skrydstrup, T. A convenient and simple procedure for the

preparation of nitrate esters from alcohols employing LiNO3/(CF3CO)2O. Tetrahedron Lett.
2005, 46, 6205-6207.
148.

Fotopoulou, T.; Iliodromitis, E. K.; Koufaki, M.; Tsotinis, A.; Zoga, A.; Gizas, V.;

Pyriochou, A.; Papapetropoulos, A.; Andreadou, I.; Kremastinos, D. T. Design and synthesis of
nitrate esters of aromatic heterocyclic compounds as pharmacological preconditioning agents.
Bioorg. Med. Chem. 2008, 16, 4523-4531.
149.

Cui, J.; Gropeanu, R. A.; Stevens, D. R.; Rettig, J.; Campo, A. D. New photolabile

BAPTA-based Ca2+ cages with improved photorelease. J. Am. Chem. Soc. 2012, 134, 7733-7740.
150.
platelet

Iyobe, A.; Uchida, M.; Kamata, K.; Hotei, Y.; Kusama, H.; Harada, H. Studies on new
aggregation

inhibitors

1.

Synthesis

of

7-nitro-3,4-dihydroquinoline-2(1H)-one

derivatives. Chem. Pharm. Bull. (Tokyo) 2001, 49, 822-829.
151.

Ren, L.; Lei, T.; Ye, J. X.; Gong, L. Z. Step-economical synthesis of tetrahydroquinolines

by asymmetric relay catalytic friedlander condensation/transfer hydrogenation. Angew. Chem.
Int. Ed. Engl. 2012, 51, 771-774.
152.

Bézière, N.; Goossens, L.; Pommery, J.; Vezin, H.; Touati, N.; Hénichart, J.-P.;

Pommery, N. New NSAIDs-NO hybrid molecules with antiproliferative properties on human
prostatic cancer cell lines. Bioorg. Med. Chem. Lett. 2008, 18, 4655-4657.
153.

Andrade, C. T.; Barros, L. A. M.; Lima, M. C. P.; Azero, E. G. Purification and

characterization of human hemoglobin: Effect of the hemolysis conditions. Int. J. Biol.
Macromol. 2004, 34, 233-240.

138	
  
	
  

	
  
	
  

154.

Safo, M. K.; Abraham, D. J. X-ray crystallography of hemoglobins. In Hemoglobin

Disorders Molecular Methods and Protocols; Nagel, R. L., Eds.; Humana Press: 2003; 82, pp 119.
155.

Perutz, M. F. Preparation of haemoglobin crystals. J. Cryst. Growth 1968, 2, 54-56.

156.

Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.;

Keegan, R. M.; Krissinel, E. B.; Leslie, A. G. W.; McCoy, A.; McNicholas, S. J.; Murshudov, G.
N.; Pannu, N. S.; Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S. Overview
of the CCP4 suite and current developments. Acta Crystallogr. Sec. D: Biol. Crystallogr. 2011,
67, 235-242.
157.

Cambillau, C.; Horjales, E. Tom: A frodo subpackage for protein-ligand fitting with

interactive energy minimization. J. Mol. Graphics 1987, 5, 174-177.
158.

Emsley, P.; Cowtan, K. Coot: Model-building tools for molecular graphics. Acta

Crystallogr. Sec. D: Biol. Crystallogr. 2004, 60, 2126-2132.

139	
  
	
  

	
  
	
  

VITA

Tanvi Mahesh Deshpande was born on December 23, 1989 to the parents Mahesh and Charulata
Deshpande. She received a Bachelor of Pharmacy degree from Mumbai Educational Trust
Institute of Pharmacy, University of Mumbai, India in July 2011. Subsequently, she was enrolled
in the Virginia Commonwealth University’s School of Pharmacy, Pharmaceutical Sciences
graduate program with a concentration in Medicinal chemistry in August 2011.
	
  

140	
  
	
  

